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ABSTRACT 
Calcium-sensing receptor (CaSR) belongs to the family C of G-protein coupled receptor 
(GPCR), playing an important role in regulating numerous biological processes in response to 
extracellular calcium levels. CaSR is the key regulator of parathyroid hormone secretion, which 
in turn influences calcium homeostasis. More notably, CaSR is also expressed in cancer cells 
upon the initiation of bone metastasis. However, the molecular basis of Ca
2+
/CaSR mediated 
bone metastasis is not clear. Human prostate tissue microarrays are first used to measure CaSR 
expression in both normal human prostate and prostate cancer tissue. Our tissue microarray 
studies reveal that CaSR is expressed in prostate cancers. The CaSR expression level of 
metastatic prostate cancer tissues found in the bone is higher than that of the primary prostate 
cancer tissues found in prostate cancer tissue localized in the prostate. This finding led us 
hypothesize that this increase of CaSR expression is likely a result of the prostate cancer cells 
adapting to the new, calcium rich environment and, thereby enhances their capacity to colonize 
in bone. To test this hypothesis, we investigate the role of CaSR in the cellular process of bone 
metastasis by knocking down CaSR expression in PC-3 prostate cancer cells with shRNA. It is 
found that PC-3 cells with reduced expression of CaSR exhibit a significant increase in cell 
apoptosis and cell invasion compared to wild type PC-3 cells. In addition, epithelial-
mesenchymal transition (EMT) biomarkers, such as vimentin and smooth muscle actin increase, 
E-cadherin and γ-catenin decrease in PC-3 cells with knocked down CaSR. This suggests that 
CaSR may inhibit cell apoptosis and cell invasion, while promoting mesenchymal-epithelial 
transition (MET) when cancer cells begin to colonize the bone. The bone environment with high 
calcium plays an important role in MET of cancer metastasis due to the prevention of apoptosis 
via CaSR. Similar results were observed for breast cancer cells MDA-MB-231. We further 
observed that the CaSR mediated signaling in PC-3 cells, including calcium oscillation, IP3 
production, and ERK activation is different from HEK 293 cells transfected with CaSR. 
Altogether, such biased CaSR signaling pathway in cancer cells is consistent with differentiated 
expression level and locations of CaSR in PC-3 cells and HEK 293 cells transfected with CaSR. 
To unwind the origin for the differential Ca2+/CaSR mediated signaling in cancer cells, we 
performed various experiments using mass spectrometry, RT-PCR, RNA and DNA sequencing, 
glycosylation and Western blot to explore the possibility of different isoforms, deletion, 
mutation, or different glycosylation patterns in CaSR. We have found a new form of CaSR as a 
monomer on the cell membrane in prostate and breast cancer cells. It has a different molecular 
weight (120KD) instead of expected dimer band with MW of 250KD.  
This first observation of low molecular weight CaSR isoform with altered signaling 
pathway in PC-3 cells is possibly shared by other cancers, especially in bone metastasis and 
likely applicable for other chronic diseases, like FHH and ADH. This reveals its new role in 
aiding cancer cells in colonizing bone. Bone environment with high calcium is likely to play an 
important role in MET of cancer metastasis due to the inhibition of apoptosis through CaSR. 
New type of cancer therapy against bone metastasis can be further developed by reducing CaSR 
at bone environment as well as by modulating extracellular calcium signaling in bone 
environment. 
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1 INTRODUCTION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
1.1 Cancer and cancer process 
             Based on Prostate Cancer Statistics, in 2011, 209,292 men in the United States were 
diagnosed with prostate cancer and 27,970 men died from prostate cancer. 220,297 women and 
2,078 men in the United States were diagnosed with breast cancer. Based on Breast Cancer 
Statistics, 40,931 women and 443 men in the United States died from breast cancer (the most 
recent year numbers available in Centers for Disease Control and Prevention 
http://www.cdc.gov/cancer/breast/statistics/). Prostate cancer patients have 65%-75% incidence 
of bone metastasis. Bone metastasis occurs in about 70% of patients with metastatic breast 
cancer. It is important to understand molecular bases of cancer and cancer metastases.   
             Cancer is a group of cells have unlimited proliferation with spread to other tissue and 
organs. The causes of cancer include chemical environment, radiation, infection, and genetic 
inheritance. Normal cells will go through programmed cell death, called apoptois, when they 
have disease or get destructed or reach biological aging. However, cancer cells have gene 
mutations, which stop them to induce programmed cell death when they have disease. Moreover, 
cancer cells acquire the ability to proliferate uncontrollably. These will make cancer cells live 
permanently.  
              There are many mechanisms demonstrating the carcinogenesis. The popular one is 
epithelial-mesenchymal transition (EMT) (1). Epithelial cells are like cobblestone, non-motile, 
and non-invasive. Epithelial markers are E-cadherin, Claudin, Occludin, Desmoglein, 
Cytokeratins, etc. Mesenchymal cells are elongated, motile, and invasive. Mesenchyaml markers 
are N-cadherin, Vimentin, Fibronectin, Snail1/2, Smooth muscle actin, etc. As shown in Fig.1.1, 
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EMT and the reverse process mesenchymal epithelial transition (MET) are originally used to 
describe the feature of the development of tissues and organs in embryogenesis and in wound 
healing. In embryogenesis, when multipotent stem cells are needed to differentiate all kinds of 
cell types, EMT happened. When it is time for differentiated stem cells to develop the tissue and 
the organ, MET happened.  
 
 
 
Figure 1.1 Adaptation of metastatic cells to a foreign environment. Cited from “A Perspective on 
Cancer Cell Metastasis” Christine L. Chaffer, et al. Science 2001, 331, 1559 (79). 
               
 EMT and MET were regarded as characteristics of cancer later since cancer cells have 
many similarities as stem cells. EMT initiates the invasion (2). First, cancer cells decrease E-
cadherin expression and lose cell-cell conjunction. Then cancer cells break through basement 
membrane and enter bloodstream through intravasation. Cancer cells arrive at new organ with 
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bloodstream and enter new organ through extravasation. MET is believed to participate in the 
establishment and stabilization of distant metastases by allowing cancer cells to regain epithelial 
properties and integrate into distant organs. Today, however, which factors trigger cells to go 
through EMT or MET are still unclear. It is very important to understand the molecular basis of 
cancer and bone metastasis. This dissertation addresses molecular mechanism for the origin of 
bone metastasis mediated by calcium sensing receptor and extracellular calcium signaling.  
1.2 Cancer and bone metastasis 
               Metastasis is the spread of cancer from primary organ to a new organ or a new sit. Bone 
metastasis is the spread of cancer from primary organ to bone. Cancer cells breaking away from 
the primary tumor enter the bloodstream. When they arrive at bone with bloodstream, they attach 
to the wall of blood vessel and move through it into bone. 
The most common primary cancers that will metastasize to bone are prostate cancer, 
breast cancer, and lung cancer (2). Prostate cancer always causes osteoblastic lesions in bone. 
Lung cancer always causes osteolytic lesions. Breast cancer always causes mixed lesions. 
Osteolytic lesion means that cancer cells lead to bone being broken down without new bone 
being laid down. Osteoblastic lesion means cancer cells leads to new bone forming instead of 
destruction. Although the osteoblastic lesion is harder, the structure of the bone is abnormal and 
is also easy to be broken. 
               Bone is mostly made up of calcium phosphate. It is the reserves of calcium. There are 
three types of cells in bone: osteoblast, osteocyte, and osteoclast. Osteoblast cell functions as 
bone forming. Osteoclast cell functions as bone resorption or bone destruction. Osteocyte is 
inactivated osteoblast.  When osteoclast breaks down bone, the local calcium concentration is 
very high. 
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Figure 1.2 Stages of Bone Metastasis in Prostate Cancer. Cited from “Metastasis to Bone: 
Causes, Consequences and Therapeutic Opportunities” Gregory R. Mundy Nat Rev Cancer. 2002 
Aug; 2(8):584-93. 
 
There are several hypotheses for the bone metastasis. The first theory is called “Seed and 
Soil” Theory by Stephen Paget in 1889 (3).  Metastasis depends on cross-talk between selected 
cancer cells (the ‘seeds’) and specific organ microenvironments (the ‘soil’) (Fig 1.2). Cancer 
cells prefer bone environment to grow outside of the primary tumor location. The second theory 
is about mutation. Not all the cancer cells can develop the ability to metastasize to bone. Only 
few of them with selected mutation or somatically inherited mutation can metastasize to bone 
(4). The third theory is that tumor growth in bone requires bone resorption. Tumor cells express 
calcium-sensing receptor (CaSR) which senses local calcium concentration. Calcium support 
tumor cell survival and expansion (5). 
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             Bone is a favorable metastatic organ because of several reasons. First, it has high blood 
flow in area of red marrow. In addition, cancer cells and bone cells can communicate each other 
to survive together. Cancer cells may release chemicals that affect how the bone cells work, 
making it easier for cancer cells to get a foothold in the bone. The bone cells may also release 
hormone-like factors and growth factors to help cancer cells grow. Furthermore, in cancer cells, 
calcium can inhibit cell proliferation, enhance cell differentiation, and activate apoptosis. 
Moreover, it can inhibit angiogenesis in tumors and decrease metastatic potential. It also can 
activate the immune system. The localized high calcium concentration environment might be 
also an important factor. Increased calcium concentration activates CaSR, producing parathyroid 
hormone-related protein (PTHrP). PTHrP acts on parathyroid hormone (PTH) receptor to 
enhance receptor activator of nuclear factor kappa-B ligand (RANKL) secretion from 
osteoblasts. The increased RANKL acts on receptor activator of nuclear factor kappa-B (RANK) 
expressed on osteoclast progenitor to help it differentiate to osteoclast therefore to increase bone 
resorption (6, 7). However, the actual molecular basis for why prostate and breast cancer cells 
prefer to metastasize to bone is unknown. This dissertation addresses the role of extracellular 
calcium and CaSR mediated cancer metastasis. 
 
1.3 Calcium and calcium signaling 
      Calcium is a chemical element with atomic number of 20. It moves in and out of cell 
participating in many cellular activities and processes. In physiology, it is regarded as dietary 
supplements to improve bone mineral density and play a very important role in cardiovascular 
events. Calcium ion is an important inorganic mineral for many physiologic processes; bone 
6 
 
turnover being one of such crucial processes. It also regulates proliferation, differentiation and 
apoptosis (8-10).        
            Calcium concentration changes are also the important signals in cell physiology. The 
serum calcium concentration is about 1.8-2.2mM. However, the intracellular calcium 
concentration is only 10-100nM. Intracellular calcium store, like endoplasmic reticulum and 
mitochondria, has calcium with concentration of mM range. The big differences of calcium 
concentration among them are controlled by many calcium channels and calcium transport 
proteins and calcium receptors on cell membrane. 
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Figure 1.3 Calcium signaling: dynamics and homeostasis. Cited from Berridge et al., Nature 
Reviews MCB, Vol4, July 2003, 517.  
              As shown in Fig. 1.3, calcium channels act to maintain depolarization of heart cell and 
muscle cell during contraction and neural cell in synaptic transmission. Calcium floods into 
cytoplasm from outside of cell through calcium channel. Incoming calcium continually 
stimulates calcium release from intracellular calcium store. Increased intracellular calcium 
concentration affects many cell functions including contraction, metabolism, transcription, 
fertilization, and proliferation. 
               Contrary to calcium channels, calcium transmembrane pumps are in charge of 
decreasing intracellular calcium concentrations. Sodium calcium exchanger (NCX) removes one 
calcium ion out in exchange of three sodium ions in. Plasma membrane calcium ATPase 
(PMCA) keeps moving calcium from intracellular plasma to extracellular environment. Since 
extracellular calcium concentrations are much higher than intracellular cytoplasm, the hydrolysis 
of ATP is needed. Sarco/endoplasmic reticulum calcium ATPase (SERCA) is on ER membrane. 
It moves calcium from intracellular plasm to ER. Both PMCA and SERCA have major effects to 
maintain low calcium concentration of intracellular plasm. 
 
1.4 Extracellular calcium signaling by CaSR  
               Extracellular calcium also play very important role via calcium receptors on cell 
membrane. Calcium-sensing receptor (CaSR) is one of them. As shown in Fig 1.3, CaSR can 
sense extracellular calcium concentration and transduct the signal down to modulate 
transcription of genes, such as parathyroid hormone.         
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        Calcium-sensing receptor (CaSR) was first cloned from bovine parathyroid gland which 
plays central role in the regulation of parathyroid hormone (PTH) secretion and calcium 
metabolism(11). Parathyroid gland cells sense the concentration of serum Ca
2+
 through CaSR. If 
the Ca
2+ 
is too low, PTH secretion will increase to enhance the absorption of Ca
2+ 
by intestine 
cells and to increase the resorption of Ca
2+ 
by bone cells. This is followed by concentration of 
serum Ca
2+ 
increasing to normal level.  If the Ca
2+ 
is too high, calcitonin secretion increases to 
reduce the absorption of Ca
2+ 
by intestine cells and to inhibit the resorption of Ca
2+ 
by bone cells. 
Then the concentration of serum Ca
2+ 
will decrease to normal level (12).   
 
                CaSR belongs to the third class of G-protein-coupled receptor (GPCR). There are three 
main G-protein-mediated signaling pathways (Fig 1.4). The three pathways are categorized by 
four subclasses of G-protein, including Gαs, Gαi/o, Gαq/11 and Gα12/13. Both of the Gαs and Gαi/o 
pathways affect adenylate cyclase to produce cyclic-adenosine monophosphate (CAMP). 
Adenylate cyclase catalyzes cytosolic adenosine triphosphate (ATP) to cyclic-adenosine 
monophosphate. G-protein of the Gαs class can stimulate this reaction, while the Gαi/o class can 
inhibit this reaction. The stimulation of HEK293 cells stably expressing CaSR by calcium or 
calcimimetics decreased CAMP significantly (13). However, in another cell line such as mouse 
bone marrow-derived macrophages, the stimulation increased CAMP production (14). It suggests 
that the pathway that activation of CaSR used in terms of CAMP production is cell specific.  
 
                 Gαq/11 pathway is to activate phospholipase C-β (PLCβ). The PLCβ can catalyze the 
reaction of the cleavage of the phosphatidylinositol 4, 5-biphosphate into the inositol (1, 4, 5) 
trisphosphate (IP3) and diacylglycerol (DAG). IP3 can bind to the IP3 receptor on endoplasmic 
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reticulum (ER) membrane to release the calcium from the ER. This process can be negatively 
regulated by phosphokinase C (PKC) through the phosphorylation of Thr-888 of the CaSR. The 
release of calcium from ER can be used as a sign to demonstrate CaSR’s function. In addition, 
PLC-dependent pathway induces calcium dependent migration of pre-osteoblasts to sites of bone 
resorption (15). In cancer cells, like hepatoma cells, the block of NO production will activate 
Gαq/11-phopholipase C-beta pathway leading to an increase of intracellular calcium 
concentration, protein kinase C and mitogen-activated protein kinase activation, finally 
promoting proliferation of cells (16). 
 
 
 
Figure 1.4 Extracellular Signaling via Calcium-sensing Receptor CaSR activates PLCβ through 
Gαq/11. The PLCβ can catalyze the cleavage of the PIP2 into IP3 and DAG. IP3 can bind to the 
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IP3 receptor on ER membrane to release the calcium from the ER. The figure is cited from Hofer 
et al., Nature Reviews MCB, Vol 4, July 2003. 
 
              Gα12/13 pathway modulates the control of cell shape and cell migration via the activation 
of GTPase, Rho. Activation of Gα12/13 results in rho-mediated actin polymerization and 
membrane ruffling. Rho is involved in the CaSR mediated calcium oscillation by extracellular 
amino acid stimulation and the serum response element (SRE) related gene transcription. In 
addition, Gα12/13 pathway modulates release of E-cadherin and beta-catenin. With respect to bone, 
Gα12/13 pathway modulates osteoblast differentiation and osteoclastogenesis through Wnt3a-beta-
RANKL (17).  
               CaSR stimulation also activates G-protein independent pathways, like mitogen-
activated protein kinase (MAPK). Epidermal growth factor receptor (EGFR) , p38 mitogen-
activated protein kinases (MAPK) (18), extracellular signal-regulated kinase (ERK) (19), filamin 
(20, 21), and protein kinase B (PKB) (19) are also involved in the intracellular signaling 
transduction by the stimulation of CaSR. CaSR-Src-Ras-Raf-MEK-ERK pathway has been 
found in many cell lines after CaSR activation. This pathway is overlapped with PLC pathway 
because CaSR activation through PLC resulting in PKC activation also can lead to activation of 
ERK (22). In NIH/3T3 cells, c-Jun N-terminal kinase (JNK) cascade signaling can be activated 
by CaSR stimulation (23). In rat and mouse cells, p38 MAPK phosphorylation was detected after 
CaSR activation (24). Another G-protein independent pathway that CaSR stimulates is the 
antiapoptotic protein kinase (Akt), also called protein kinase B, signaling (25). 
              Camodulin (CaM) is a calcium-binding protein in cytoplasm. It transduces calcium 
signal by binding calcium and calcium related proteins. It is reported that the interaction between 
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CaSR and CaM is important to maintain calcium oscillation of release from and reentering the 
calcium store in cells. Chen Zhang from our lab found that CaM facilitates L-Phe and calcium 
cooperatively induced calcium oscillation pattern in HEK293 cells transfected with CaSR. The 
disruption of CaM’s binding site on C-tail of CaSR will decrease the agonist driven insertional 
signaling effects. 
 
1.5 Structure, ligand, and potential binding sites for calcium and other ligands of CaSR 
              CaSR can be stimulated by a lot of various substances, like cations, amino acids, 
polyamines, polypeptides, aminoglycoside antibiotics, pharmacological agents, ionic strength, 
and pH (26, 27). Cations include La
3+
, Gd
3+
, Ca
2+
, Ba
2+
, Sr
2+
, and Mg
2+
. Ca
2+
 and Mg
2+
 are two 
intracellular divalent cations which have physiological functions. Amino acids include 
phenylalanine, tryptophan, histidine, alanine, glutamate, leucine, and arginine. Polyamines 
include spermine and spermidine. Aminoglycoside antibiotics include neomycin, tobramycin, 
gentamycin, and kanamycin. Pharmacological agents are chemical compounds designed to 
mimic or inhibit CaSR’s function. NPS R-568 is the successfully used calcimimetic, which can 
increase the sensitivity of CaSR to calcium as CaSR agonist. NPS 2143 is the successfully used 
calcilytics, which can decrease CaSR’s sensitivity as CaSR antagonist. Extracellular calcium 
signaling mediated by CaSR is highly cooperative. This process is well demonstrated by the 
response curves of PTH, intracellular calcium oscillation as a function of extracellular calcium. 
Cooperative binding means the binding of one ligand to CaSR affects the binding of other ligand. 
Cooperative binding can be positive or negative. Positive cooperativity means successive ligand 
molecules appear to bind with increasing affinity. Negative cooperativity means the binding of a 
molecule to the first subunit makes more difficult the binding of substrate to the second 
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molecule. Hill coefficient number n is always used to describe cooperativity. If n is larger than 1, 
it suggests positively cooperative binding. If n is less than 1, it suggests negatively cooperative 
binding. If n is equal to 1, it suggests noncooperative binding. Chen Zhang in Yang lab recently 
reported that L-Phenylalanine modulates wildtype CaSR in a heterotropic positive cooperative 
way, decreasing the EC50 close to activating mode. L-Phenylalanine also rescues inactivating 
mutation of CaSR in a homotropic positive cooperative way. Miedlich et al. found that 
calcimimetic (NPS R-568) also has positive cooperative effect on calcium binding to CaSR, 
eliciting calcium oscillation. The sequence from Arg (873) to His(879) might be the cooperative 
binding site.  
               Like other family C of GPCR. CaSR has a large extracellular domain (612 amino 
acids), a transmembrane domain and a cytosolic tail.  The extracellular domain shares 27% 
sequence homology to mGluR1 (28). Based on mutational studies, extracellular domain of CaSR 
was reported to play an important role in response to various ligands including extracellular 
calcium.  Despite of great effort in crystallization, the structure of CaSR has not reported (Fig 
1.5).  Fig 1.5 shows the modeled ECD structure by Yang lab. 
 
 
Figure 1.5 Topology of Calcium-sensing Receptor. CaSR is dimer with two Venus-Flytrap(shape 
of a plant) structures with lower part of transmembrane domain and intracellular domain. The 
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figure is cited from “Multiple Ca2+-binding sites in the extracellular domain of the Ca2+-sensing 
receptor corresponding to cooperative Ca
2+
 response. Huang Y, Biochemistry. 2009 Jan 
20;48(2):388-98”. 
 
 
            The amino acids 36-513 form the Venus-flytrap structure, which are conserved binding 
sites for ligand in GPCR C family. Our previous lab members have predicted 5 potential calcium 
binding sites using software of MODELER and MetalFinder (29). Site 1 is surrounded by 
residues Ser147, Ser170, Asp190, Tyr218, and Glu297. Site 2 is surrounded by Asp215, Leu242, 
Ser244, Asp248 and Gln253. Site 3 is surrounded by Glu224, Glu228, Glu229, Glu231, and 
Glu232. Site 4 is surrounded by Glu350, Glu353, Glu354, Asn386, and Ser388. Site 5 is 
surrounded by Glu378, Glu379, Thr396, Asp398 and Glu399 (29). Among these predicted 
calcium bonding sites, site 1 located at the hinge region between two domains is important to the 
binding of calcium and calcium-induced conformational change in the CaSR. This binding site 
was reported recently to close to the Phe binding site in CaSR (30, 31). There are 13 amino acids 
involved in glutamate binding in Venus Fly Trap region of the metabotropic glutamate receptor 1 
(mGluR1).Yusheng Jiang in our lab also reported that there is a calcium binding site at similar 
location of the mGluR1 close to the glutamate binding site (32). Interestingly, a potential calcium 
binding site was also reported to adjacent to GABA binding site in GABAB receptor (33). Based 
on these common structural features, extracellular calcium and agonists such as amino acid are 
likely to regular CaSR, mGluR and GABAB receptor cooperatively. However, most of these 
findings for the role of extracellular calcium in regulating CaSR’s activity were studied using 
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HEK cells with a transfection of CaSR. The role of CaSR in endogenous cell lines, especially in 
cancer cells, has not been well explored yet. 
1.6 Calcium sensing receptor in cancer 
  Leung et al. demonstrated that inhibition of microfibrillar-associated protein 5(MFAP5) 
can decrease ovarian tumor growth and metastasis in vivo (34). The mechanism is related to 
calcium dependent FAK/CREB/TNNC1 signaling pathways. Calcium channel protein Orai 1 and 
STIM1 also play important roles in breast cancer cell migration and metastasis. 
Ca
2+
 is a candidate mediator of prostate cancer bone metastasis (35), which is secondary 
malignant growth in bone of primary cancer. Prospective epidemiologic studies indicate that men 
with higher levels of serum calcium have the higher risk of advanced prostate (36). Serum 
calcium levels are influenced by CaSR. Ca
2+
 can act with the CaSR to prevent apoptosis and 
define a novel mechanism by which calcium ions can regulate cell survival(37, 38).                                 
        As shown in Table 1.1, CaSR is widely expressed in many tissues of human body, such as 
parathyroid, breast, prostate, placenta, blood vessels, colon, liver, bone, nerve system, etc. The 
function of CaSR is not only associated with calcium homeostasis but also other conditions like 
blood vessels’ calcification , osteoporosis and cancer (39).  
It is still not clear whether CaSR plays a role in promotion or inhibition of cancer 
development. It depends on the type of cancer. In parathyroid adenoma/carcinoma and colorectal 
cancer, CaSR’s expression decreases compared to in normal tissues (40) or in well-differentiated 
tumor tissues. The functions of CaSR in these cancers are to inhibit proliferation and improve 
differentiation. In tumors of nerve system, CaSR is expressed in favorable tumors, while it 
inhibits proliferation. Therefore, in parathyroid cancer, colorectal cancer, and neural cancer, 
CaSR functions as a tumor suppressor. In leydig cancer and ovarian cancer, CaSR enhances 
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cancer cells’ proliferation (41). In astrocytoma, activation of CaSR increased the cellular 
proliferation. In breast cancer and prostate cancer, CaSR facilitates metastasis to bone (42, 43). 
Therefore, in theses cancer types, CaSR functions as a tumor enhancer. 
 
 
 
 
 
 
 
Table 1.1Comparison of CaSR’s oncogenic role and tumor suppressor role in cancers 
 Oncogenic  Role Tumor Suppressor  Role 
Parathyroid Cancer  Down-regulation of CaSR is seen in parathyroid 
carcinomas 
Colon Cancer  CaSR is highly expressed in normal and well-
differentiated regions of colonic neoplasms 
Breast Cancer High expression of CaSR in breast cancer 
patient has high chance to have bone 
metastasis 
Promote cell proliferation 
Highly expressed CaSR in bone metastatic 
cells  
CaSR is expressed higher in normal breast tissue 
than that of cancer 
Prostate Cancer Promote cell proliferation  
Highly expressed CaSR in bone metastatic 
cells  
 
Leyding Cancer CaSR is a promalignant receptor  
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Astrocytoma Activation of CaSR increase the cellular 
proliferation  
 
Ovarian Cancer Ca
2+ stimulates proliferation of OSE cells 
through the activation of CaSR 
 
 
 
          Since CaSR is primarily expressed on epithelial cells of parathyroid gland, the roles of 
CaSR in parathyroid cancer and parathyroid adenoma are studied. It is found that CaSR mRNA 
and protein expression decreased in parathyroid adenomas and carcinomas compared to normal 
parathyroid gland (44). Moreover, the activation of CaSR is related with down-regulation of 
parathyroid proliferation (45). The exact mechanism under these phenomena is not known yet. 
However, these processes seem to involve expression of cyclin D1 and overexpression of 
regulator of G-protein signaling 5 (RGS5).  
         CaSR is expressed in many areas of colons, including basal region of crypt, the serosa, 
sub mucosa, and the neural ending. Some researchers demonstrated that CaSR is expressed both 
in cytoplasm and membrane of epithelial cells in colon (46, 47). As in parathyroid cancer, CaSR 
expression is suppressed during the process of colon tumorigenesis. Researchers found that 
CaSR is highly expressed in well-differentiated regions of colonic neoplasms and nearly lacking 
in poorly differentiated regions (48). CaSR suppresses cell proliferation of normal colon 
epithelial cells and early stage of cancer cells. Β-catenin, E-cadherin, Wnt pathway, and receptor 
tyrosine kinase-like orphan receptor 2 (Ror2) are involved in CaSR signaling in colon cancer 
(49). 
        Recent genomic analysis reported that there are quite a few mutations of CaSR in 
cancer. 
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Table 1.2 CaSR mutations in cancers from COSMIC 
AA Mutation Histology CDS Mutation Primary Tissue Histology Subtype 
p.A2E Carcinoma c.5C>A skin Squamous cell  
p.D23N Carcinoma c.67G>A lung Squamous cell 
p.R66H Carcinoma c.197G>A Ovary  
p.E80K Carcinoma C.238G>A Breast  
p.T103S Carcinoma C.308C>G Breast  
p.V104L Carcinoma C.310G>A kidney Clear cell renal cell 
p.R205C Carcinoma C.613C>T liver  
p.F311V other C.931T>G thyroid neoplasm 
p.G316S adenoma C.946G>A prostate  
p.H344L carcinoma C.1031A>T breast  
p.E610K adenoma C.1828G>A prostate  
p.N639K carcinoma C.1917C>A breast  
p.G670W carcinoma C.2008G>T prostate adenocarcinoma 
p.T732A carcinoma C.2194A>G breast  
p.T808A carcinoma C.2422A>G breast  
p.W818L carcinoma C.2453G>T prostate adenocarcinoma 
p.R886Q carcinoma C.2657G>A breast  
p.V894I carcinoma C.2680G>A breast  
p.Q983E carcinoma C.2947C>G breast  
p.R1041W adenoma C.3121C>T prostate  
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Figure 1.6 Gene exons of calcium-sensing receptor. There are 7 exons in calcium-sensing 
receptor. Exon 2, 3, 4, 5, 6, and part of exon 7 covers extracellular domain. Exon 7 covers 
transmembrane and intracellular domains. 
 
Fig 1.6 describes gene exons of CaSR. Due to development in gene sequence and human 
genomics, people have found many results of disease mutations in cancers. Working with Cassie 
Miller in Yang lab, we have summarized CaSR mutations in cancers as shown in Table 1.2 from 
COSMIC database. 
 
1.7 CaSR in Bone Metastasis  
        CaSR is considered to be involoved in breast cancer and prostate cancer, especially in 
bone metastasis. CaSR is expressed in ductal epithelial cell of breast tissue, which is involved in 
regulating milk calcium concentration. However, both ductal and lobular breast cancer tissues 
express CaSR. The expression of CaSR is higher in MDA-MB-231 breast cancer cells, which has 
increased bone metastatic potential, than that in MCF-7 and T47D breast cancer cells with low 
tendency to metastasize to bone (50, 51). The same as in breast cancer, CaSR is also expressed 
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more highly in bone metastatic prostate cancer cell line C4-2B and PC-3 cells than that in non-
bone-metastatic cell line LNCaP cells (52). 
         In breast cancer, it is found that calcium stimulates normal breast epithelial cell 
proliferation and promotes differentiation through CaSR. CaSR also can increase the 
chemosensitivity of breast cancer cells (53). In breast and prostate cancer, CaSR is found to 
mediate bone metastasis. It is involved in the vicious cycle of bone metastasis through its 
interactions with the parathyroid hormone related peptide (PTHrP). Mihai et al. found that most 
breast cancer patients with high expression of CaSR had bone metastasis (54). They think CaSR 
can be a biomarker to predict the potential risk of bone metastasis in breast cancer patients. Liao 
et al. found that PC-3 prostate cancer cells (obtained from metastatic site of bone) have higher 
levels of CaSR mRNA than LNCaP cells (obtained from lymph node). Increasing calcium 
concentration increases cellular growth of PC-3 cells but not of LNCaP cells. Knockdown of 
CaSR expression reduces cell growth of PC-3 cells both in vitro and in vivo in a murine model of 
prostate cancer metastasis.  
            Since bone has high calcium concentration environment, CaSR might play a role in 
mediating bone metastasis of prostate and breast cancer. We need to know what the exact role of 
CaSR is in cancer bone metastasis and what kind of mechanism for CaSR mediates bone 
metastasis and what the difference of signaling pathway between normal cell and cancer cell is. 
 
1.8 Challenges in Research of CaSR 
            There are several challenges that prevent us from understanding molecular basis of 
calcium sensing receptor mediated calcium signaling in cancer. First, the crystal structure of 
CaSR has not been resolved possibly due to large number of glycosylation. There are altogether 
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8 N-linked glycosylation sites: Asn90, Asn130, Asn261, Asn287, Asn446, Asn468, Asn488, and 
Asn541. 
             Second, it is possible that the transcripts of CaSR may have many variants and isoforms. 
More than 300 mutations have been reported for human diseases related to familial hypocalciuric 
hypercalcemia (FHH), neonatal severe hyperparathyroidism and primary hyperparathyroidism 
(55). Recently there are more than 300 mutations related to cancer were reported in Cosmic 
(Table 1.2 lists some of them). However, such the molecular bases if such mutations are not 
clear. In addition, there may be a heterogenous expression of different forms of CaSR in 
different cell lines and tissues.   
              Third, the endogenous expression level in cell lines and tissues are not high. Commonly, 
the structure and function of CaSR were investigated through transfecting of CaSR plasmid into 
Human Embryonic Kidney 293 cell (HEK293) with an overexpression. To observe the 
endogenous expression and function of CaSR in human tissues, like cancer tissues, we need to 
obtain a lot of tissue samples from patients. However, it is difficult to obtain human bone 
samples, especially cancer metastasized bone samples due to limited availability. Such low 
expression level of CaSR makes it difficult to use other methods such as mass spectrometry to 
identify CaSR and its associated proteins from cell lines (see Chapter 6).  Using DNA 
sequencing to identify mutations was also much challenged due to low expression and unknown 
splicing and frame shift (chapter6).   
               Fourth, CaSR experiences dynamic action involving in folding of CaSR in the ER, 
glycosylation at Golgi, dimerization, trafficking to the plasma membrane, and endocytosis 
(desensitization).  Such dynamic change process requires us to have a sensitive assay to probe its 
location, distribution and molecular identify. One related challenge to this issue is that the 
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capability of antibodies used to probe the expression of CaSR.  Some of them are not specific 
and has limited sensitivity (see chapter 4, Table 4.1).   
             Fifth, to investigate the role of CaSR in cancer cells, we can apply knocking CaSR down 
strategy. siRNA transfection is a widely used method to effectively decrease expression of target 
gene. However, this decrease of expression is not stable and only last for several days. If we need 
to observe long time effects of knocking CaSR down, we have to find another way, like using 
shRNA transfection to set up a stable cell line.  
             Sixth, the signaling pathway of CaSR may have variants and isoforms. As shown in Fig 
1.4, to investigate the mechanism of CaSR’s function, we need to figure out a clear signaling 
pathway from complicated signaling network. 
 
1.9 Objectives and Approaches of the Study and Overview of the Dissertation 
             In this dissertation, we aim to understand the molecular basis of Ca
2+
/CaSR mediated 
calcium signaling in cancer bone metastasis.  
              Chapter 1 here, we provide the general background for the proposed studies. 
              Chapter 2 describes methods we used for the proposed studies. 
              In Chapter 3, we propose to determine the expression of CaSR in human prostate and 
breast cancer tissue with bone metastasis and without bone metastasis (Aim 1). We will obtain 
human prostate tissue microarray containing normal human prostate, human prostate cancer 
tissue with or without bone metastasis. It also contains prostate cancer tissue obtained from bone. 
Immunohistochemistry (IHC) staining of CaSR will be performed on human prostate tissue 
microarray. The intensity of CaSR expression among different groups will be analyzed with the 
help from pathologist from Emory University and using Aperioimage software (56). After 
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getting the intensity data of different groups, statistic analysis will be done by SPSS or R 
software. 
               In chapter 4, we will investigate the role of extracellular calcium and CaSR in the 
cellular process of bone metastasis of prostate and breast cancer (Aim 2).   
   CaSR expression will be knocked down in human prostate cancer cell line PC-3 cell 
which was got from bone of prostate cancer patient and breast cancer cell lines MDA-MB-231 
by shRNA. The effect of decreased expression of CaSR on cell proliferation, cell invasion, and 
cell attachment will be investigated. MTT or BrdU tests are used to measure cell proliferation. 
Boyden Chamber is used to test cell migration and cell invasion. Western blot is used to observe 
the change of expression of other related proteins. Apoptosis kit is used to measure the cell 
apoptosis induced by extracellular calcium concentration change. Based on the finding of the 
role of CASR in protection of apoptosis and MET, we propose to future animal studies to test the 
role of CASR in bone metastasis of Prostate and breast cancer.  
   In chapter 5, we aim to investigate extracellular calcium and CASR mediated calcium 
signaling and trafficking in cancer cells (Aim 3).  We will first examine the intracellular calcium 
concentration difference or oscillation difference between normal and cancer cell. Fura-2 will be 
used to measure the calcium concentration using fluorescence microscope. The effect of different 
extracellular calcium concentration on calcium oscillation in normal and cancer cell can be 
examined separately. In addition, the calcium signal pathway involving Mitogen-activated 
Protein Kinase (MAPK) pathway will be examined since MAPK pathway (ERK1/2, p38 and 
JNK) is also involved in cell response to calcium in normal cell and is also an important pathway 
for tumor growth. The difference of this pathway between normal and cancer cell would help to 
understand the tumor genesis.  
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             In Chapter 6, we aim to understand molecular basis for the differential calcium signaling 
in cancer cells. We will first examine the expression of CaSR in different cancer cells and 
relative quantification. Second, we examine their cellular locations and trafficking using 
florescence imaging. Third, we will perform glycosylation experiments to investigate the 
glycosylation pattern of CaSR in PC-3 cells. Fourth, we will apply RT-PCR and sequencing to 
examine whether there is mutation or deletion in CaSR sequence of PC-3 cells. Fifth, we will 
perform mass spectrometry analysis of the CaSR in cancer cells. In Chapter 7, we will discuss 
our major findings of our studies and the significance of these studies.  
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2 MATERIALS AND METHODS 
2.1 Tissue microarrays  
Tissue arrays containing both prostate cancer tissue and normal prostate tissue (PR807 
and PR955) were purchased from the Biomax Company (Rockville, MD www.biomax.us). The 
tissue samples, including normal prostate tissue, primary prostate cancer tissue in patients with 
or without bony metastases, prostate cancer tissue from bony metastases, and prostate cancer 
tissue from other metastatic sites in two tissue microarrays, which were combined to enlarge the 
sample size. Altogether, there were 24 samples of normal prostate tissue, 108 samples of primary 
prostate cancer tissue (i.e., obtained from the prostate gland), and 4 samples of prostate cancer 
tissue obtained from bony metastases. Among the 108 prostate cancer patients represented by the 
two arrays in which cancer tissue was obtained from the prostate, 12 of them had coexistent bony 
metastases while 96 of them did not. Tissue specimens were not available from the bony 
metastases in these 12 patients.  
2.2 Immunohistochemistry (IHC) 
          The slides were first deparaffinized by heating at 60°C for 2 hours. Then they were boiled 
in 10 mM citrate sodium solution (pH 6.0) for 10 min for antigen retrieval, followed by 
incubation in 3% H2O2 for 5-10 min to block endogenous peroxidase. After blocking in normal 
goat serum for 20 min, the slides were incubated with rabbit polyclonal anti-CaSR antibody 
raised against a synthetic peptide whose sequence is within the first third of the receptor’s N-
terminal extracellular domain (Sigma, St. Louis, MO) at 4°C overnight. The specificity of the 
antibody was documented by negative control IHC (i.e., by omitting the first antibody) and the 
western blot as described in Results. Biotinylated anti-rabbit antibody was used as secondary 
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antibody. Staining was visualized using 3,3'-Diaminobenzidine (DAB) tetrahydrochloride, and 
slides were counterstained with hematoxylin. 
2.3 Analysis of IHC staining 
The tissue microarrays were read by a pathologist (B.L.) blinded to the identity of the 
tissue sections. The staining intensity in any given tissue section was given a grade of 1, 2 or 3. 
A higher grade indicates a higher intensity of staining. The area ratio stands for the percentage of 
the area stained for CaSR over the total epithelial cellular area. The final pathological score was 
obtained by multiplying the intensity grade by the area ratio. The tissue microarray was also 
scanned using a Hamamatsu/Olympus Nanozoomer 2.0HT whole slide image scanner 
(Hamamatsu Photonics K.K., Hamamatsu, SZK).  The whole slide image was viewed in the 
Aperio ImageScope program (Vista, CA) and analyzed with the Aperio positive pixel count 
algorithm similar to methods previously described. The default hue (brown) for the positive pixel 
count algorithm was used.  The positivity (number of positive pixels over total number of pixels) 
of each sample was obtained for statistical analysis. 
2.4 Cell culture 
   Human prostate cancer cells lines, including C4, C4-2, C4-2B, DU145, LNCaP, and PC-3, 
and human breast cancer cells lines, including MCF-7 and MDA-MB-231, were obtained from 
the American Type Culture Collection (ATCC) (Manassas, VA, USA). MDA-MB-231 cells 
were cultured in Dulbecco's modified Eagle's medium (D-MEM), which contains 1.8 mM 
calcium and was supplemented with 10% fetal bovine serum (FBS) and 2.0 mM L-glutamine. 
C4, C4-2, C4-2B, DU145, LNCaP, and PC-3 cells were cultured in RPMI1640 medium, which 
has 0.42 mM calcium and was supplemented with 10% fetal bovine serum (FBS) and 2.0 mM L-
glutamine. MCF-7 cells were cultured in modified Eagle’s medium, supplemented with 10% 
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fetal bovine serum (FBS) and 2.0 mM L-glutamine. All the cells were incubated at 37°C in a 
humidified atmosphere of 5% CO2 in air. For subculturing, the cell monolayer was washed twice 
with phosphate-buffered saline (PBS) and incubated with a trypsin-EDTA solution (0.05% 
trypsin, 0.25% EDTA) for 10 min at 37°C to detach the cells from the dish. Trypsin was then 
inhibited by adding FBS at 37°C. Cells were resuspended in culture medium for reseeding. 
2.5 Western blot 
       Cells were harvested and then suspended in 200 μl of Western blot lysis RIPA buffer on 
ice for 15 min. After centrifugation at 15000 × g for 15 min at 4 °C, the supernatants were 
collected. The proteins were separated on 12% SDS-PAGE. After electrophoresis, equal amounts 
of protein from each sample were transferred to a nitrocellulose membrane. The membrane was 
blocked with 5% nonfat milk in Tris-buffered saline (TBS) and then incubated with mouse anti-
human CaSR monoclonal antibody (Santa Cruz, ADD 1:1000) as well as a mouse anti-human 
GAPDH antibody (Abcam 1:3000) separately overnight at 4℃. After washing three times with 
TBS containing 0.1% Tween, the membrane was incubated at room temperature for 1 h with 
goat anti-mouse secondary antibody (Biorad) diluted with TBST (1:10,000). The protein bands 
were then visualized using an enhanced chemiluminescence reaction system (Biorad). 
Quantitative analysis of the intensity of bands was performed using ImageJ software (National 
Institutes of Health). 
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2.6 Knock down of CaSR expression in prostate cancer cells 
 
Figure 2.1 Lentiviral delivery of shRNA and the mechanism of RNA interference in mammalian 
cells. Lentivirus carrying shRNA sequence enters the cell and goes through reverse transcription 
to form pre-integration complex. The complex can integrate into genomic DNA to produce 
shRNA through normal transcription process. Produced shRNA can transfer into siRNA to 
interfere targeted gene translation. 
http://en.wikipedia.org/wiki/Small_hairpin_RNA
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 Short hairpin RNA (shRNA) directed at the CaSR in pLKO.1 vector was purchased from 
Open Biosystems. pLKO.1-CaSR (Open Biosystems) was co-transfected into HEK293T cells 
with psPAX2 and pMD2.G (Addgene) into HEK-293T cells to pack the CaSR-targeting virus. 
The psPAX2 plasmid contains genes that package the viral particles, while pMD2.G contains 
genes necessary for producing the viral envelope. The hairpin sequence for the interfering CaSR 
is: 
“CGGGCTGGGTGTGTTTATCAAGTTCTCGAGAACTTGATAAACACACCCAGCTTTTT”. 
pLKO.1-Control (Addgene), when co-transfected with psPAX2 and pMD2.G into HEK-293T 
cells, produces the control virus, which has a shRNA with a scrambled sequence that has no 
target gene. On the second and the third days after transfection, the medium containing the 
viruses was collected and filtered to infect PC-3 prostate cancer cells. PC-3 cells were seeded at 
70% confluency in 60 mm dishes. 1 mL of medium containing the virus was added to 4 mL of 
cell culture medium in the dish with the seeded cells. Polybrene was added to increase the 
efficiency of infection. After 24 hours, fresh medium was added to the cells and a final 
concentration of 3 μg/ml puromycin was added to select infected cells. Surviving cells were 
seeded by limiting dilution in 96-well plates to obtain stably infected clones.   
 
2.7 Transfection of wild type CaSR and silent mutant CaSR into cells 
All the transfections of CaSR plasmids were carried out using lipofectamine 2000 (Life 
Technologies). Wild type CaSR in pcDNA3.1 was transfected into LNCaP cells or PC-3 control 
cells to overexpress the wild type receptor. The plasmid encoding the CaSR with a silent 
mutation that doesn’t alter the amino acid sequence but interferes with the knockdown of the 
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receptor by the shRNA was transfected into PC-3 CaSR in which the CaSR had been knocked 
down using shRNA as described above, using the forward primer, gggagtcttcattaagttccgcaac, and 
the reverse primer, agcacaaaggctgtcaggaaaatg. 
 
2.8 Cell viability assay 
    The cells were suspended in 96-well plates at a density of 2×10
4
 cells per well. After 24 h 
they were treated with various concentrations of calcium for different time intervals (0–72 h). 
After the treatment, 20 ul of a solution of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium(MTS) (Promega) was added to 100 
μl medium in each well. The MTS is a formazan dye that is reduced to a purple precipitate by 
NAD(P)H in viable but not in non-viable cells.  An ELISA reader was used to measure the 
absorbance at 490 nm.  
 
2.9 Cell migration and cell invasion assays 
     Biocoat matrigel invasion Boyden chambers (BD Biosciences Company) were used to 
measure cell migration and invasion. According to the protocol, 2.5×10
4 
PC-3 cells were seeded 
in control migration chambers that only have a membrane with pores between the upper and 
lower chambers or the invasion chambers, which have matrigel matrix above the membrane. 22 
hours later, cells that did not pass through the pores in the membrane were removed. The 
membrane was then removed and stained with DAPI to permit counting of cells on the underside 
of the membrane (i.e., cells that had migrated through the membrane). The blue nuclei of cells on 
the underside of the membrane were counted using a fluorescence microscope. Cell migration 
was defined as the number of cells passing through the membrane into the migration chamber. 
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Cell invasion was defined as the percentage of the cells passing through the matrigel and 
membrane in the invasion chamber relative to the cells passing through just the membrane in the 
migration chamber.  
 
2.10 Cell scratch assay 
Cell scratch assay is a method to examine cell migration. Cells were firstly seeded into 
wells of 6-well plate. A wound was created in a monolayer of cells, growing in a six-well plate, 
by a sterile 10 μl plastic pipette tip. Cells at both sides of the wound tend to migrate to the empty 
wound place for more surviving space. The photograph was taken after 0, 24, and 48 hours later 
under microscope. 
 
2.11 Cell apoptosis by flow cytometry 
Cell apoptosis of PC-3 and MDA-MB-231 cells was measured using dead cell apoptosis 
kit from Life Technologies. According to the protocol, the cells were firstly treated with different 
calcium concentrations or apoptosis-inducing drugs. Secondly, the cells were harvested and 
washed in cold phosphate-buffered saline. Then the cells were stained with annexin V Alexa 
Fluor 488 and propidium iodide at room temperature for 15 minutes. Finally, the cells were 
loaded into a Fortessa flow cytometer. The fluorescence was measured at emission of 530nm and 
575nm using 488nm excitation. Annexin V positive but propidium iodide negative cells were 
regarded as apoptotic cells. 
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2.12 Transfection of CaSR and CaSRGFP  
HEK293 cells were seeded onto a coverslip in a 60mm dish after detaching. 2 µg of 
CaSR or CaSRGFP (endowed by Dr. Thakker of Oxford University) or dsRED-ER (to define 
Endoplasmic Reticulum) and the corresponding volume of lipofectamine 2000 were added into 
the dish according to the invitrogen protocol. The media was changed 4 hours later. 
 
2.13 Intracellular calcium measurements 
After incubation for 20 min with the fluorescent probe Fura-2/AM (2 μM) in Ringer’s 
buffer, cells were washed with a 0.5 mM calcium bath solution containing 140 mM NaCl, 5 mM 
KCl, 0.55 mM MgCl2, 0.5 mM CaCl2, and 10 mM HEPES. The coverslip was placed in a 3mL 
quartz cuvettes containing bath buffer. The extracellular calcium concentrations were changed by 
adding calcium buffer with different concentrations, from 0.5mM, to 2mM, 3mM, 4mM, 5mM, 
7.5 mM, 10 mM sequentially. Excitation wavelengths were 340 and 380 nm, and fluorescence 
emission was measured at 510 nm. The ratio of the emission excited by 340 nm and 380 nm is 
regarded as intracellular calcium concentration. The green fluorescence of GFP was excited at 
488 nm and the emission was measured at 510 nm. 
  
2.14 Transfection rate measured by Flow cytometry 
HEK293 cells were transfected with CaSRGFP plasmid. Cells in suspension were fixed in 
4% paraformaldehyde for 15 min at room temperature. After being washed three times with PBS, 
cells in suspension were incubated in blocking buffer for 30 minutes at room temperature. Cells 
were then incubated with primary antibody of human CaSR at room temperature for 20 minutes 
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and at 4°C overnight. The next day, the cells were washed with PBS and incubated with the 
Alexa555 fluorochrome-conjugated secondary antibody (Invitrogen). Finally, cells were loaded 
into the Fortessa flow cytometer to measure the fluorescence. 
 
2.15 ERK phosphorylation  
      HEK293 cells transfected with CaSR and PC-3 cells were treated with 0.2% BSA cell 
culture medium without fetal bovine serum overnight. The next day cells were washed with 
Ringer’s buffer without glucose without calcium three times. Then the cells were treated with 
different concentration of calcium buffer at 37 degree for 10 minutes. The cells were collected 
and lysed in RIPA buffer, loaded on 12% SDA-PAGE gel. Polyclonal ERK antibody and 
polyclonal phosphor-ERK antibody from Cell Signaling Technology were used to detect the 
proteins. 
2.16 IP1 measurement 
IP1 is transformed from IP3. IP1 production induced by G-protein coupled receptor 
activation was measured by IP-One ELISA kit. Cells were stimulated by calcium for 1 hour and 
were lysed. The supernatant was transferred to an ELISA plate, added with IP1-HRP conjugated 
and anti-IP1 monoclonal antibody. After 3 hours of incubation, TMB substrate was added to 
incubate 20 minutes. Finally, stop solution was added and the plate was read at 450 nm with 
optical correction. 
2.17 Immunoprecipitation 
       40 dishes of PC-3 cell were scraped down and lysed in RIPA buffer with protease 
inhibitor. Control agarose beads were washed with immunoprecipitation buffer for three times 
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before added to lysis supernatant. The supernatant were precleaned by control agarose beads for 
30min. The control agarose was washed with immunoprecipitation buffer for three times. The 
flow through then were incubated with calcium-sensing receptor antibody overnight. Protein A 
agarose was washed with immunoprecipitation buffer for three times before being added to cell 
lysis flow through and CaSR antibody. The agarose, antibody and cell lysis supernatant were 
shaked at 4 degree 30min. The agarose bead was washed with immunoprecipitation buffer for 3 
times and eluted by loading buffer with beta-mecaptoethanol. The supernatant were loaded on 
the SDS-PAGE gel after centrifugation. The gel was stained with Coomassie blue after 
electrophoresis. 
2.18 Biotin Assay 
         Cells attaching on the dish were treated with 30µg/ml disulfide-cleavable biotin in 
PBS for 30 minutes at 4 degree after being washed with PBS for three times. Then the cells were 
washed with PBS several times to remove the biotin. Cells were lysed in RIPA buffer. CaSR was 
immunoprecipitated with anti-CaSR antibody and protein A agarose. Samples were denatured in 
SDS sample buffer without beta-mercaptoethanol and electrophoresised by 8% SDS-PAGE. 
Biotinated-CaSR was visualized using VECTASTAIN ABC immunoperoxidase reagent. 
2.19 RT-PCR 
Total RNA was isolated from PC3 cell line with illustra RNAspin Mini kit (GE, 
Germany). Total RNA (1 μg) was reverse transcribed in a 20 μl reaction with a reverse 
transcription assay system (Thermal Scientific Phusion RT-PCR kit). Reverse transcription was 
done at 25 °C for 10 minutes, 48 °C for 30 minutes and 95 °C for 5 minutes. The PCR primer 
sequences designed for CaSR are indicated in table 2.1. PCR was done in 50 μl reaction system: 
10 μl 5×Phusion buffer, 1 μl 10mM dNTPs, 4 μl cDNA, 2 μl primers, 0.5 μl DNA polymerase, 
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32.5 μl water. The reaction is 99°C 30s, 25-40 cycles of 99°C 10s, 58°C 10s, and 72°C 40s, then 
72°C 5min. 
Table 2.1 Primers for CaSR 
Primers Sequences 
PC3-CaSRE-12-For GAGTCTGTGGAATGTATCAGGTATAATTTCCGTGG 
PC3-CaSRE-12-Rev GAGGAGGCATAACTGACCTGGGGAATGTAG 
PC3-CaSRE-23-For CTGGGGCTCTTCTACATTCCCCAGGTCAGTTATGCC 
PC3-CaSRE-23-Rev CCGTAGGTGCTTCAGGACCTGCCACGCCTC 
PC3-CaSRE-56-For GTATAGTGATGAGACAGATGCCAGTGCCTGTAACAAG 
PC3-CaSRE-56-Rev TGAATTCACTACGTTTTCTGTAACAGTGCTGCCTCCAC 
PC3-CaSRE-E7-Rev GGTGTTGCGGGATGGCTTGAAGAGAATGATGTAG 
PC3-CaSRE-E7-For CTACATCATTCTCTTCAAGCCATCCCGCAACACC 
PC3-CaSRE-E7-2-Rev CTGCTTTTCTGGGCCTCCAGGGAGTTCTGGTG 
PC3-CaSRE-E7-2-For CTACGCACCAGAACTCCCTGGAGGCCCAGAAAAGCAG 
PC3-CaSRE-E7-3-Rev GAAGTCATCTGGGCACTTGTTACAGGCACTGGCAT 
PC3-CaSRE-E7-4-Rev CCTCCAGCTCCTGGTTGCGGTAGCTTGAC 
PC3-CaSRE-E7-4-For GTCAAGCTACCGCAACCAGGAGCTGGAGG 
PC3-CaSRE-E7-5-Rev GATGCACGCCAGCAAGCCAAAGCTGGCTG 
PC3-CaSRE-E7-6-Rev CTCTCGGTTGGTGGCCTTGACAATGGGTGTG 
PC3-CaSRE-E7-6-For CACACCCATTGTCAAGGCCACCAACCGAGAG 
PC3-CaSRE-E5-Rev CTCCCTGGAGAACCCACTCCACAGGATTTTCTC 
PC3-CaSRE-E6-Rev GCAGTCTCGGCTGCAGTTGGAGAAGGGCAC 
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2.20 Statistical analysis 
Statistical analyses of differences between groups were carried out by R software (R 
Development Core Team) using Student’s t test, the Wilcox test, or the Kolmogorov-Smirnov 
test according to whether the samples were normally distributed or not. If both groups were 
normally distributed with the same variance, Student’s t test was used. If neither of the two 
groups had a normal distribution, the Wilcox test was used. If one group was normally 
distributed but the other was not, the Kolmogorov-Smirnov test was used. A value of P < 0.05 
was taken as indicating a statistically significant difference. All of the tests are two-sided. 
Pearson’s correlation was used to analyze the correlation among groups. P < 0.05 was taken to 
indicate a statistically significant correlation.   
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3 PROSTATE CANCER METASTATIC TO BONE HAS HIGHER EXPRESSION OF 
THE CALCIUM-SENSING RECEPTOR (CASR) THAN PRIMARY PROSTATE 
CANCER  
3.1 Abstract  
The calcium-sensing receptor (CaSR) is the principal regulator of the secretion of 
parathyroid hormone and plays key roles in extracellular calcium (Ca
2+
o) homeostasis. It is also 
thought to participate in the development of cancer, especially bony metastases of breast and 
prostate cancer. However, the expression of CaSR has not been systematically analyzed in 
prostate cancer from patients with or without bony metastases. By comparing human prostate 
cancer tissue sections in microarrays, we found that the CaSR was expressed in both normal 
prostate and primary prostate cancer as assessed by immunohistochemistry (IHC). We used two 
methods to analyze the expression level of CaSR. One was the pathological score read by a 
pathologist, the other was the positivity% obtained from the Aperio positive pixel count 
algorithm. Both of the methods gave consistent results. Metastatic prostate cancer tissue obtained 
from bone had higher CaSR expression than primary prostate cancer (P <0.05). The expression 
of CaSR in primary prostate cancers of patients with metastases to tissues other than bone was 
not different from that in primary prostate cancer of patients with or without bony metastases (P 
>0.05). The expression of CaSR in cancer tissue was not associated with the stage or status of 
differentiation of the cancer. These results suggest that CaSR may have a role in promoting bony 
metastasis of prostate cancer, hence raising the possibility of reducing the risk of such metastases 
with CaSR-based therapeutics.  
This work has been published at Receptors & Clinical Investigation. 2014 1(6): e270. 
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3.2 Introduction 
    The calcium (Ca
2+
)-sensing receptor (CaSR) plays a central role in calcium homeostasis by 
sensing small changes in the level of extracellular calcium (Ca
2+
o) and regulating parathyroid 
hormone (PTH) secretion and renal calcium excretion so as to normalize Ca
2+
o. Naturally 
occurring mutations cause familial hypocalciuric hypercalcemia (FHH) , neonatal severe 
hyperparathyroidism (NSHPT)(57) and autosomal dominant hypocalcemia with hypercalciuria 
(ADHH)(58). The CaSR was first cloned from bovine parathyroid glands (59) and belongs to 
class C of the G protein-coupled receptors (GPCR). CaSR also has been suggested to modulate 
adipocyte function (60), carcinogenesis (61), insulin secretion (62), mineralization of the bony 
matrix (63) and pathological calcification (64), etc. Recently, much more attention has been paid 
to possible roles of CaSR in various types of cancer, including colon cancer (65), breast cancer 
(66), prostate cancer (67,68), ovarian cancer (69), Leydig cell cancer (70), gastric cancer (71), 
insulinoma (72), and glioblastoma (73).  
        In breast and prostate cancer, CaSR has been suggested to participate in bony 
metastasis. It has been implicated in a vicious cycle of bony metastases through its modulation of 
parathyroid hormone related peptide (PTHrP) secretion by cancer cells (74). Mihai et al. found 
that most breast cancer patients with a high expression of CaSR in malignant tissue obtained 
from the breast had bony metastases (75). They suggested that CaSR can serve as a biomarker to 
predict the potential risk of bony metastasis in breast cancer patients. Liao et al. found that PC-3 
prostate cancer cells (originally obtained from a bony metastasis) have higher levels of CaSR 
mRNA than LNCaP cells (obtained from a lymph node). Increasing the extracellular calcium 
concentration stimulates growth of PC-3 cells but not of LNCaP cells. Knockdown of CaSR 
expression reduces growth of PC-3 cells both in vitro and in vivo in a murine model of prostate 
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cancer metastasis. However, these authors did not compare CaSR expression in the bony 
metastases with that in the primary cancers in the prostate. Therefore, the relative levels of CaSR 
expression in primary prostate cancers and in metastases to bone and other sites as well as the 
associated implications for the metastatic process are not clear. 
In this study, we performed immunohistochemistry (IHC) to detect CaSR expression in 
various benign and malignant prostatic tissues on human prostate cancer tissue microarrays. Our 
results show that CaSR expression is higher in bony metastases of prostate cancer than in 
specimens of primary prostate cancer.  
 
3.3 Results 
3.3.1 Patient information 
 Figure 3.1 and Figure 3.2 shows normal prostate tissue with a regular glandular 
structure.  CaSR is expressed both in the cell membrane and in the cytoplasm of all of the 
epithelial cells. Primary prostate cancer tissue also expresses CaSR in all of the cancer cells with 
the same cellular localization, regardless of whether the patients have bony metastases or not. 
Prostate cancer tissue obtained from bone does not typically have a glandular structure, and the 
cancer cells cluster together, expressing much more CaSR than in prostate cancer sections 
obtained from the prostate or from non-bony metastases, as shown by the deep brown color in 
the bony metastases. Two cases of prostate cancer tissues obtained from the abdominal wall also 
did not have a glandular structure but show less staining than the cancer tissues obtained from 
bone.  
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Figure 3.1 Examples of IHC staining of CaSR in tissue microarrays. Four groups of tissues are 
shown: normal prostate tissue, primary prostate cancers in patients with bony metastasis, primary 
prostate cancers in patients without bony metastasis, and prostate cancer from bone. 
(Magnification 40×). 
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Figure 3.2 IHC staining of CaSR in prostate tissue microarray PR955. Normal prostate tissue: 
H1-H11 and G9-G12 Primary prostate cancer: A1-A12, B1-B12, C1-C12, D1-D12, E1-E12, and 
F1-F12. Prostate cancer from bone: G3-G8 (G5 and G6 were damaged). Prostate cancer from 
abdominal wall: G1-G2. (Magnification 4×) 
 
 
CaSR expression levels in patient tissues were analyzed using two complementary 
methods. As shown in Table 3.1, the median pathological score of normal prostate tissue was 
180 with a 25th percentile of 95 and 75th percentile of 214, and the median pathological score of 
all prostate cancer tissue samples obtained from prostate was 190 with a 25th percentile of 115 
and 75th percentile of 240. All of the 4 prostate cancer tissues obtained from bone had the same 
pathological score of 300 (i.e., all had intensity grades of 3 with 100% of the cells staining 
positive for CaSR). Two cases of prostate cancer tissues obtained from the abdominal wall had a 
score of 120.  
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Table 3.1 Patient information and CaSR expression level 
 Case Age Pathological Score (%) 
(multiply intensity by 
area) Median (25
th
, 
75
th
 percentiles) 
Positivity (%) 
Median (25
th
, 
75
th
 percentiles) 
 
 
Normal 
prostate tissue 
 
 
Primary 
prostate cancer 
tissue 
24 28-84 180 (95,214) 0.07 (0.03,0.14) 
108 20-82 190 (115,240) 0.07(0.03,0.16) 
Metastatic 
prostate cancer 
tissue from bone 
4 59-69 300 (300,300) 0.39 (0.36,0.40) 
 
 
The Aperio positive pixel count algorithm is a method for measuring area and intensities 
in IHC results (76, 77). The positivity%, which describes the number of positive pixels over the 
total number of pixels of each sample, was used, in addition to the use of the pathological score, 
to analyze the expression level of CaSR. The semi-quantitative values obtained by this method 
are summarized in Table 2 for detailed comparison. The median positivity% of normal prostate 
tissue was 0.07 with a 25th percentile of 0.03 and 75th percentile of 0.14, and the median 
positivity% of all prostate cancer tissue samples obtained from prostate was 0.07 with a 25th 
percentile of 0.03 and 75th percentile of 0.16. All of the 4 prostate cancer tissues obtained from 
bone had a positivity% of around 0.39. Therefore the use of these two different methods yielded 
quite consistent results, showing a significant correlation by linear regression between 
pathological score and image analysis (Figure 3.3). 
  
42 
 
 
 
Figure 3.3 Correlation between pathological score and positivity%. (R
2
 = 0.35, P = 0.001) Every 
tissue sample was evaluated by methods of pathological score and positivity% separately. 
 
Statistical analysis of the pathological scores showed that there was no difference in 
CaSR expression between the normal prostate tissues and the primary prostate cancer tissues 
(Fig. 3.4A) (P = 0.65). There were only 4 samples of prostate cancer tissue metastatic to bone, 
and consequently, the Kolmogorov-Smirnov test was used, since it can be employed with small 
sample sizes. The metastatic prostate cancer tissues obtained from bone have higher CaSR 
expression than the prostate cancer specimens obtained from prostate (P = 0.001) or the normal 
prostate tissue (P = 0.004).  Among the 108 samples of prostate cancer obtained from prostate, 
12 samples were from patients having bony metastasis (tissue from the bony metastases of these 
patients were not available), and these had the same CaSR expression in the primary prostate 
cancer specimens as that in the 96 samples from primary prostate cancer of patients having no 
bony metastases (P = 0.67). (Figure 3.4B)   
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The positivity% results are shown in Figure 3.4 C and D. The conclusions are the same. 
There was no difference in CaSR expression between the normal prostate tissues and the primary 
prostate cancer tissues (P = 0.97). The metastatic prostate cancer tissues obtained from bone have 
higher CaSR expression than the prostate cancer specimens obtained from prostate (P = 0.003) or 
the normal prostate tissue (P = 0.003). Samples from primary prostate cancer tissue of patients 
having bony metastasis had the same CaSR expression as the primary prostate cancer samples 
from patients having no bony metastases (P = 0.07). 
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Figure 3.4 Pathological score and positivity% for CaSR expression in each group, as quantitated 
in prostate tissue microarrays. A: Comparison of pathological scores of normal prostate tissue, 
primary prostate cancer tissue, and prostate cancer tissue from bone. B: Comparison of 
pathological scores of primary prostate cancer tissue from patients with bony metastasis and 
primary prostate cancer tissue from patients without bony metastasis. C: Comparison of 
positivity% of normal prostate tissue, primary prostate cancer tissue, and prostate cancer tissue 
from bone. D: Comparison of positivity% of primary prostate cancer tissue from patients with 
bony metastasis and primary prostate cancer tissue from patients without bony metastasis.  
3.3.2 Correlation of CaSR expression with cancer stage 
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In the arrays studied here, there were 29 cases of stage 2 cancer, 44 cases of stage 3 
cancer, and 33 cases of stage 4 cancer. The scatter plot in Figure 3.5A shows that there is no 
correlation between the pathological score for the CaSR and stage of the cancer (R
2
 = 0.011, P = 
0.54). The data on the stages of the patient’s cancers are shown in Table 3.2. The positivity% 
results also showed that there is likewise no correlation (R
2
 = 0.007, P = 0.41) as in Figure 3.5 D. 
 
Table 3.2 Pathological tumor (T) stage and positivity% for expression of CaSR in primary 
prostate cancer tissues of patients with different stages of prostate cancer in array PR955  
T Stage Cases 
(N) 
Pathological Score (%) 
(intensity multiplied by area) 
Median (25
th
, 75
th
 percentiles) 
Positivity (%)Median (25
th
, 
75
th
 percentiles) 
 
2 
 
29 
 
180 (85,200) 
 
0.06 (0.03,0.13) 
3 44 190 (158,255) 0.06 (0.03,0.14) 
4 33 180 (160,200) 0.08 (0.05,0.16) 
 
The correlation P value for stage and pathological score is 0.54. The correlation P 
value for stage and positivity is 0.41. 
 
3.3.3 Correlation of CaSR expression with Gleason score    
Cancers with a higher Gleason score are more aggressive and have a worse prognosis. The 
scatter plot in Figure 3.5B shows that there is no correlation between the pathological score for 
CaSR expression and the Gleason score (R
2
 = 0.003, P = 0.08). Information about the patients on 
whom a Gleason score was available is shown in Supplemental Table 3.3. There is also no 
correlation between Gleason score and positivity% (R
2
 = 0.009, P = 0.31) as shown in Figure 3.5 
E. 
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Table 3.3 Pathological scores and positivity% for expression of CaSR in primary prostate cancer 
tissues of patients with different Gleason scores in array PR955  
Gleason 
score 
Cases 
(N) 
Pathological Score (%) 
(intensity multiplied by area) 
Median(25
th
, 75
th
 percentiles) 
Positivity (%)Median (25
th
, 
75
th
 percentiles) 
4 1 200 0.26 
5 1 170 0.25 
6 12 175 (89,221) 0.09 (0.04,0.23) 
7 34 195 (160,255) 0.08 (0.04,0.14) 
8 16 190 (93,214) 0.10 (0.02,0.17) 
9 32 185 (150,200) 0.05 (0.03,0.10) 
10 11 180 (145,200) 0.15 (0.04,0.24) 
 
The correlation P value for Gleason score and pathological score is 0.08. The 
correlation P value for Gleason score and positivity is 0.31. 
 
3.3.4 Correlation between CaSR expression and prostate specific antigen (PSA) 
concentration    
PSA, secreted by the epithelial cells of the prostate gland, is often elevated in the presence 
of prostate cancer or other prostate disorders. The normal PSA level should be less than 4 ng/mL. 
The scatter plot in Figure 3.5C shows that there is no correlation between the pathological score 
for CaSR expression and the PSA concentration in blood (R
2
 = 0.013, P = 0.07). Information 
about the patients in whom PSA values were available is shown in Supplemental Table 3.4. 
There is also no correlation between PSA and positivity% (R
2
 = 0.075, P = 0.05) as shown in 
Figure 3.5 F.  
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Table 3.4 Pathological scores and positivity% for expression of CaSR in primary prostate cancer 
tissues of patients with different PSA concentrations in array PR955  
PSA(ng/mL) Cases 
(N) 
Pathological Score (%) 
(intensity multiplied by area) 
Median (25
th
, 75
th
 
percentiles) 
Positivity (%) Median 
(25
th
, 75
th
 percentiles) 
 
0-4 
 
5 
 
160 (160,200) 
 
0.02 (0.02,0.03) 
4-10 9 200 (160,200) 0.03 (0.02,0.04) 
10-20 20 185 (120,200) 0.06 (0.04,0.14) 
20-40 13 255 (190,285) 0.12 (0.08,0.16) 
>40 10 198 (190,253) 0.10 (0.03,0.12) 
 
The correlation P value for PSA and pathological score is 0.07. The correlation P 
value for PSA and positivity is 0.05. 
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Figure 3.5 Relationship between pathological score and positivity% for CaSR expression and 
cancer progression stage, Gleason score, and PSA concentration in blood. A: Relationship 
between pathological score of CaSR expression in primary prostate cancers and cancer stages. B: 
Relationship between pathological score of CaSR expression in primary prostate cancers and 
Gleason Score. C: Relationship between pathological score of CaSR expression in primary 
prostate cancers and PSA concentration. D: Relationship between positivity% of CaSR 
expression in primary prostate cancers and cancer stages. E: Relationship between positivity% of 
CaSR expression in primary prostate cancers and Gleason Score. F: Relationship between 
positivity% of CaSR expression in primary prostate cancers and PSA concentration.  
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3.4 Discussion 
In this study, we did not find a difference in CaSR expression between normal prostate 
tissue and primary prostate cancer tissue. The metastatic prostate cancer tissues studied here that 
were obtained from bone have higher CaSR expression than primary prostate cancer tissues. For 
the second tissue microarray (designated PR955 by the supplier), most of the tissues were 
obtained from prostate. Some were obtained from metastatic sites: 6 from bone and 2 from the 
abdominal wall. The samples of prostate cancer obtained from bone in these arrays are very 
scarce and fragile. Sections from two such bony metastases were damaged. Therefore, only four 
were available for statistical comparison with the staining from the other tissues due to 
limitations of patient sample availability. However, these four prostate cancer tissues obtained 
from bone all showed the highest level of CaSR expression among the tissues studied here, as 
reflected by the largest possible pathological score of 300 for each specimen. 2 metastases from 
the abdominal wall both had scores of only 120. This may suggest that high expression of CaSR 
in the cancer tissue from bone is a consequence of their localization in the bony environment, 
e.g., expression of the CaSR may be upregulated by factors in the bony microenvironment (see 
below). It is also possible that bone selects for metastatic cells with high CaSR expression and 
resultant increased potential to metastasize to bone because bone is a “fertile field” (78) for them 
when they express a high level of CaSR.  
 
Importance of bone environment 
Bone is a favored metastatic site for some cancer cells (79). These metastatic sites are 
characterized by high rates of bone turnover (80), with continuous breakdown of bone by 
osteoclasts, followed by replacement of the missing bone by osteoblasts. In some active lacunae 
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where bone resorption is taking place, the extracellular calcium level can reach as high as 8-40 
mmol/L (81). The high calcium concentration within this microenvironment could induce the 
expression of the CaSR in cancer cells. High concentrations of calcium and calcimimetics (i.e., 
allosteric CaSR activators) have, in fact, been shown to upregulate expression of the CaSR in 
normal tissues, such as parathyroid gland (82, 83). Elevated extracellular calcium concentrations 
stimulate parathyroid hormone related peptide (PTHrP) production by prostate cancer cell lines 
(84), which could increase bone resorption near bony metastases of prostate cancer, thereby 
producing a favorable environment for tumor growth and providing a growth advantage for 
metastatic cancer cells having high CaSR expression. 
          There is abundant literature addressing possible targets for the treatment of prostate 
cancer (85, 86). The seed and soil theory is a popular one (87). Cancer cells are regarded as the 
seeds and the bony environment as the soil. Some believe that the therapeutic target should be 
the seed. From the point of view of our study, treatments targeting both the seed (e.g., prostate 
cancer cells with high CaSR expression) and soil (i.e., high local levels of Ca
2+
o in bone) could 
be a better therapeutic direction in the clinic. That is, a therapeutic approach combining 
inhibition of bone resorption using a bisphosphonate (88), for example, suppression of CaSR 
activity with a calcilytic, e.g., a negative allosteric modulator of the receptor (89). While such a 
combined approach has not been reported to our knowledge, decreasing the level of expression 
of the CaSR in PC-3 cells in a murine model of prostate cancer metastasis to bone, reduced the 
metastatic burden in bone.  
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Comparison with other studies 
CaSR is considered to be an important factor in bony metastases of some types of cancer. 
Breast cancer tissues from patients with bony metastases have higher expression of CaSR than 
that of breast cancer from patients without bony metastases. In our study, we didn’t see any 
differences between CaSR expression in the primary prostate cancers of patients with bony 
metastases and that in the primary prostate cancers that had not metastasized to bone. This might 
be due to the CaSR having different functions in different types of cancer (90, 91). Huang et al. 
demonstrated that CaSR expression was significantly higher in more tumorigenic prostate cancer 
cell lines and in prostate cancer tissue specimens than in the normal prostate cells (92). However, 
this study did not use IHC to detect the expression of CaSR protein in situ, but extracted the 
protein from the normal tissue and cancer tissue then performed western blot analysis. The 
number of tissue specimens examined was also small. 
Adams, et al. reported that hematopoietic stem cells engraft in bone, at least in part, 
because of CaSR. Hematopoietic stem cells from CaSR-/- mice exhibited diminished adhesion to 
extracellular matrix proteins, even though they were normal in their capacities to differentiate, 
migrate and home to bone. Therefore, if, as we have suggested here, CaSR expression increases 
after prostate cancer cells arrive at bone (93), this increased CaSR could potentially enhance the 
capacity of cancer cells to localize in the bone by a similar mechanism(s). This hypothesis will 
be tested in following Chapters.  
 
3.5 Conclusion 
          Our tissue microarray study suggests that CaSR expression may increase after prostate 
cancer cells arrive at bone. These results lead us to hypothesize that the increase of CaSR 
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expression could result from the process of cancer cells adapting to the bony environment and, 
thereby, enhancing their capacity to colonize in bone. This hypothesis will be tested in Chapters 
4-5. We cannot exclude, however, the possibility that small numbers of prostate cancer cells with 
high CaSR expression have greater metastatic potential for bone rather than the remaining 
prostate cancer cells localized in prostate. Stimulation of PTHrP secretion by the high level of 
CaSR expressed by this subpopulation of cells might enhance their capacity to establish 
metastases in bone. Given the limited number of prostate cancer tissues obtained from bony 
metastases studied here due to difficulties in obtaining such samples, it would be important to 
extend the study in the future to additional cases of bony metastases of prostate cancer. We have 
contacted Dr. Osunkoya at Emory for human prostate cancer samples from bone. These tissue 
samples will be analyzed in the future. 
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4 INVESTIGATION OF THE ROLE OF EXTRACELLULAR CALCIUM AND CASR 
IN THE CELLULAR PROCESS OF BONE METASTASIS OF PROSTATE AND 
BREAST CANCER  
4.1 Abstract 
The calcium-sensing receptor (CaSR) is a key component of the system maintaining 
extracellular calcium homeostasis and is the principal physiological regulator of the secretion of 
parathyroid hormone (PTH). In Chapter 3, we reported that the metastatic prostate cancer tissue 
obtained from bone had higher CaSR expression than primary prostate cancer (P <0.05) by 
comparing human prostate cancer tissue sections in microarrays using IHC. The expression of 
CaSR in primary prostate cancers  patients with metastases to tissues other than bone was not 
different from that in primary prostate cancer patients with or without bony metastases (P >0.05).  
To test the hypothesis that CaSR may have a role in promoting bony metastasis of cancer, 
several studies using both prostate cancer and breast cancer cell lines were performed. We first 
reported that a prostate cancer cell line (PC-3) that metastasizes to bone has a higher level of 
expression of the CaSR than does a prostate cancer cell line (LNCaP) that has no tendency to 
metastasize to bone. In addition, we have shown that knocking CaSR down in PC-3 cells and 
breast cancer cells increased cell apoptosis and cell invasion. Knocking CaSR down also reduced 
the expression of E-cadherin, integrin, and matrix metalloproteinases (MMP-2 and MMP-9). 
Further, knocking CaSR down caused phenotypic changes associated with epithelial-
mesenchymal transition, i.e., decreasing E-cadherin and γ-catenin and increasing smooth muscle 
actin and vimentin. Similar results were obtained with knock down of CaSR in the breast cancer 
cell line, MDA-MB-231. Our results suggest that CaSR is highly expressed in prostate and breast 
cancer cell lines and may participate in preventing cell apoptosis of cancer cells, inhibiting their 
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invasion, and promoting mesenchymal-epithelial transition.  These results support our hypothesis 
that CaSR-mediated signaling process may facilitate cancer cell colonization of bone with high 
calcium in vivo by preventing calcium induced apoptosis.  
 
4.2 Introduction 
As discussed in Chapter 1 (1.6), calcium plays key roles in stimulating or inhibiting 
cancer development. It has been shown to inhibit cell proliferation (94), enhance cell 
differentiation (95, 96), activate or inhibit apoptosis (97, 98), inhibit angiogenesis (99), and 
decrease metastatic potential (100). There are numerous calcium channels and efflux 
mechanisms that regulate the cellular entry or exit of calcium ions. Changes in the intracellular 
calcium concentration affect a variety of cellular functions, including muscle contraction (101), 
cellular metabolism (102), gene transcription (103), fertilization (104), proliferation, etc. Many 
of these functions are regulated by calcium acting as an intracellular second messenger. The 
cloning of the cell surface extracellular calcium (Ca
2+
o)-sensing receptor (CaSR) in 1993, 
however, proved that calcium could also serve as an extracellular first messenger (105). 
The CaSR is a class C, G protein -coupled receptor that senses Ca
2+
o as its principal 
physiological agonist. It was first identified on the cell membrane of the chief cells of the bovine 
parathyroid gland by Brown et al (59). It was then shown to be widely distributed in the human 
body (106). When the CaSR senses that Ca
2+
o in blood are too high, parathyroid cells decrease 
their secretion of parathyroid hormone (PTH). The resultant decrease in the circulating level of 
PTH produces a lowering of the blood calcium concentration by reducing tubular reabsorption of 
calcium in the kidney, decreasing calcium absorption in the intestines via the associated 
reduction in the production of 1,25(OH)2D3 by the kidney, and diminishing net release of 
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calcium from bone. Conversely, when CaSR senses that the blood calcium is too low, the 
secretion of PTH increases, thereby elevating the blood calcium concentration through increased 
release of calcium from bone, enhanced absorption of calcium in the intestines, and increased 
renal tubular reabsorption of calcium. 
        Besides CaSR’s major function in sensing Ca2+o in serum to modulate the secretion of 
PTH and other aspects of the homeostatic system regulating Ca
2+
o homeostasis, CaSR also plays 
a variety of roles in cancer. As shown in Section 1.7, CaSR was reported to act both as tumor 
suppressor or tumor promoter in an oncogene-like manner depending on the cancer type and the 
pathophysiological conditions. Researchers found that CaSR is expressed at higher levels in 
regions of well-differentiated colon cancer than in poorly differentiated areas (107). Down 
regulation of CaSR is seen in parathyroid tumors, including parathyroid carcinoma. However, 
the CaSR can have tumor-promoting actions in other cancers. In Leydig cancer cell, for example, 
CaSR is considered as a premalignant receptor (108). Todate, it is still not clear whether CaSR 
plays its principal role in promoting or inhibiting cancer development due to several challenges 
as stated in Chapter 1 (section 1.9). 
Calcium can increase cell proliferation and induce G1/S phase transition in cell cycle in 
normal cells. However, in cancer cells, this function changed due to vitamin D. Cancer patients 
always have vitamin D deficiency. Vitamin D can regulate calcium and phosphates concentration 
to inhibit cell proliferation in cancer tissues.  
           Calcium is stored at sarco/endoplasmic reticulum by SERCA3 (Sarco/endoplasmic 
reticulum calcium ATPase). Therefore, this enzyme can regulate homeostasis of intracellular 
calcium and control calcium-dependent cell activation.   Arbabian et al reported that SERCA3 
expression increased in spontaneous differentiation of Calu-3 cell (Lung Adenocarcinoma cell). 
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Fang et al, reported that calcium enhanced mouse keratinocyte differentiation. Calcium release 
from calcium store like sarco/endoplasmic reticulum also can induce cell apoptosis. Ingrid et al. 
found that release of calcium from calcium store without increasing cytosolic calcium 
concentration induced cell apoptosis of LNCaP cell (prostate cancer cell). This apoptosis is 
induced through caspase-3 and -7 in early stage. Later, caspase-9 and Bclx were involved to 
attenuate the process. 
            In the bony microenvironment, Ca
2+
o can achieve levels as high as 8-40 mmol/L near 
osteoclasts resorbing bone, which is more than sufficient to activate the CaSR expressed by cells 
in the local microenvironment (109). For cancers with bone metastasis, such as breast and 
prostate cancer, CaSR is thought to participate in the development of bony metastases. Mihai et 
al. found that the CaSR is highly expressed in breast cancer cells of patients who have a high risk 
of bony metastasis (75). They suggested that the level of CaSR expression may be a biomarker 
that could predict the risk of bony metastasis in breast cancer patients. However, the relative 
level of CaSR expression in primary prostate cancers and in metastases to bone and other sites as 
well as the associated implications for the metastatic process was not clear. In Chapter 3, we 
reported that metastatic prostate cancer tissue obtained from bone had higher CaSR expression 
than primary prostate cancer (P <0.05) by comparing human prostate cancer tissue sections in 
microarrays using IHC (110). The expression of CaSR in primary prostate cancers of patients 
with metastases to tissues other than bone was not different from that in primary prostate cancer 
patients with or without bony metastases (P >0.05).  The high expression of CaSR expression in 
bony metastatic prostate cancer tissues found by us and similar results of breast cancer found by 
others lead us to hypothesize that CaSR may have a role in promoting bony metastasis of cancer.  
57 
 
         As shown in Figs 1.1 -1.2, cancer invasion and metastasis from the primary organ 
involves transition from an epithelial to a mesenchymal phenotype (EMT). This EMT is an 
important cancer development process to induce cells that have a stem cell-like phenotype and 
tumor-initiating capability (111). On the other hand, transition from a mesenchymal to an 
epithelial phenotype (MET) may be the process that facilitates proliferation of cancer cells in the 
metastatic organ (112). For CaSR-mediated bone metastasis, Padget’s hypothesis of seeding and 
soil and prevention of apoptosis at high calcium environment have also been speculated in the 
literatures (3, 6). 
    In this study, we aim to explore the potential role of CaSR in promoting the 
development of bony metastasis in prostate cancer and breast cancer. We first examine CaSR 
expression level of several cancer cell lines that have different capabilities in bone metastasis. 
We then chose both PC-3 cells and MDA-MB-231 cells that have a high potential for 
metastasizing to bone for prostate and breast cancer, respectively.  The effects of knocking down 
expression of the CaSR in both PC-3 cells and MDA-MB-231 cells on proliferation, migration, 
invasiveness, and apoptosis have been examined. The effects of overexpression of CaSR in these 
cancer cells have also been examined. In addition, epithelial-mesenchymal transition and MET 
process have also been investigated.   
 
4.3 Results 
 
4.3.1 Expression of CaSR in prostate and breast cancer cells 
Antibody technologies, such as Western Blot and Immunhistochemistry, are commonly 
used method in cellular studies and tissue studies. We surveyed and examined several CaSR 
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antibodies from different companies (Table 4.1). ADD antibody (ab19347) againt mouse ADD 
peptide of CaSR from Abcam is a mouse monoclonal anti-CaSR antibody. It can be used as 
positive control to detect CaSR in human, bovine and rat. It was selected to be used in western 
blot. C4491 against extracellular N-terminal domain of CaSR antibody from Sigma was selected 
to be used in IHC.   
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       Table 4.1 Summary of different CaSR antibodies 
 Company Immunogen Host 
AP08361PU-N Acris  Synthetic peptide derived from the N-terminus of Rat Calcium Sensing Receptor  Rabbit  
 
AP15386PU-N  Acris A synthetic peptide from N-terminal of rat calcium sensing receptor Rabbit 
SM5143P Acris Synthetic peptide corresponding to residues (214) A D D D Y G R P G I E K F 
RE E A E E R D I (235) of Human Calcium Sensing Receptor  
Rabbit 
SP5484P  Acris Synthetic peptide of rat CaSR(12) L A W H S S A Y G P D Q R A Q(27)  Rabbit 
ab79829  Abcam Synthetic peptide: KDQDLKSRPESVECIRYNFRGFR, corresponding to N 
terminal amino acids 47-69 of Calcium Sensing Receptor  
 
Rabbit 
ab19347 Abcam Synthetic peptide: ADDDYGRPGIEKFREEAEERDI, corresponding to amino 
acids 214-235 of Human Calcium Sensing Receptor  
Mouse 
ab18200  Abcam Synthetic peptide conjugated to KLH derived from within residues 1 - 100 of Rat 
Calcium Sensing Receptor 
Rabbit 
ab62214  
 
Abcam Synthetic phosphopeptide derived from human Calcium Sensing Receptor 
around the phosphorylation site of threonine 888 (R-A-TP-L-R). 
Rabbit 
ab27493  
 
Abcam A synthetic peptide from N terminal of rat calcium sensing receptor  Rabbit 
C4491  
 
Sigma  
 
synthetic peptide corresponding to the extracellular N-terminal domain of 
human calcium-sensing receptor, conjugated to KLH  
Rabbit 
C0493  
 
Sigma  
 
peptide corresponding to amino-acids 15-29 at the extracellular N-terminus of 
calcium sensing receptor.  
Mouse 
PA1-37214  
 
Pierce 
 
Synthetic peptide corresponding to the N-terminus of rat calcium sensing 
receptor  
Rabbit 
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We first examined CaSR expression in several prostate cancer cell lines that have 
different bone metastasis potentials (113-117). Arcap E cell is epithelia like androgen refractory 
cancer of the prostate cell. Arcap M is the mesenchymal like androgen refractory cancer of the 
prostate cell. LNCaP cell is human prostate cancer cell obtained from lymph node. LNCaP cell 
and bone fibroblasts cells were injected to mice to get C4 cell. C4 cell and bone fibroblasts cells 
were injected to mice to get C4-2 cell. C4-2B cell is C4-2 cell metastasized to bone. DU145 cell 
is human prostate cancer cell obtained from brain. PC-3 cell is human prostate cancer cell 
obtained from bone. PC-3 cells are prostate cancer cell lines with a high potential for metastasis 
to bone and were originally obtained from a bony metastasis. LNCaP cells are a prostate cancer 
cell line with low metastatic potential that was originally obtained from a non-bony metastasis 
(114). HEK293 cell has no CaSR expression, being taken as negative control. HEK293 cell 
transfected with CaSR is taken as positive control. 
  As shown in Fig.4.1, western blotting of CaSR in prostate cancer cells showed a band 
immunoreactive for the CaSR at about 120 kD in the various cell lines using anti-calcium-
sensing receptor antibody (ADD ab19347 from Abcam). HEK293 cell transfected with CaSR 
show dimer CaSR of 250 kD and monomer CaSR of 15 kD. About 10
6
 cells were lysed in 200µl 
RIPA buffer. After centrifugation, about 30µl of supernatant mixed with 10 µl of sample loading 
buffer were added to run SDS-PAGE gel. Some prostate cancer cell lines showed a lower 
molecular weight band of about 110 kDa. GAPDH is used as a loading control. Quantitative 
analysis of the expression level of CaSR was determined using the band intensity ratio of band of 
CaSR at 120 kD over GAPDH at 37 kD using ImageJ (Method, chapter 2.5). As shown in Fig 
4.1, all prostate cancer cell lines have CaSR expression. CaSR expression in PC-3 cells with high 
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metastatic potential is 0.5 folds greater than in LNCaP cells with low metastasis potential. This 
result means CaSR might be an important factor involved in bony metastasis.  
 Interestingly, C4-2 has the highest expression, about 4 folds higher than that of LNCaP. 
C4-2 cell is the mixture of C4 cell and bone fibroblasts. It might be possible that bone fibroblast 
has high expression of CaSR, which makes C4-2 also has high expression of CaSR. Arcap E cell 
has 1.5 folds higher expression of CaSR than Arcap M cell. This suggests that cells with 
epithelial type have more CaSR expression. CaSR might be an epithelial marker. 
 
 
 
Figure 4.1 Expression of CaSR in prostate cancer cells. C4, C4-2, and C4-2B cells are prostate 
cancer cells obtained from mice. DU145 cells are prostate cancer cells metastasizing to brain. 
LNCaP cells are prostate cancer cells metastasizing to lymph node. PC-3 cells are prostate 
cancer cells metastasizing to bone. ARCaPE cells have an epithelial phenotype. ARCaPM cells 
display a stem-like cell phenotype. The whole cell lysates were extracted with RIPA buffer as 
described in Methods and loaded onto a gel for western blotting. This result is representative of 
three independent experiments.  
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Figure 4.2 shows the localization of CaSR in PC-3 cells by immunofluorescence. It shows CaSR 
is expressed not only on cell membrane but also cytoplasm of PC-3 cell.  
 
Figure 4.2 Localization of CaSR in PC-3 cells under confocal. PC-3 cells were permeabilized by 
0.2% triton or not, then incubated with CaSR ADD antibody, and stained with Alexa555 
conjugated secondary antibody. Blue fluorescence is DAPI staining nuclear. Red fluorescence is 
Alexa555 staining CaSR. (Confocal 63×) 
 
             Figure 4.3 shows mRNA level expression of CaSR in PC-3. PC-3 has CaSR mRNA 
expression. HEK293 is a negative control since it has no CaSR expression. The forward primer 
and reverse primer cover the region of exon3 (Fig 1.6). 
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Figure 4.3 Detection of the CaSR mRNA from PC3 cells. A total of 4 μl of the cDNA CaSR 
from PC3 were used as templates in the PCR procedure respectively. All PCR reactions were 
using forward primer 12 and reverse primer 12.  The Tm value was set to be 62 °C with 3 min 
elongation time with 30 cycles.  
 
4.3.2 High calcium concentration increase CaSR expression 
Expression of the CaSR has been reported to be higher in prostate cancer metastatic to 
bone patient samples than in that obtained from prostate per se. A possible reason underlying this 
observation was investigated using in vitro experiments. We seeded PC-3 cells in 6-well plate on 
the first day (2×10
5
 each well). On the second day, the medium was changed from RPMI1640 
medium with FBS to calcium free DMEM medium with 0.2% BSA. After overnight starving 
(cells lack nutrition of FBS and calcium), the cells were added different concentration of calcium 
chloride at the third day for 48 hours (118). On the fourth day, the cells were collected to do 
western blot. As shown in Fig 4.4, CaSR expression increased with elevation of Ca
2+
o from 0.5 
mM to 10 mM, but largely disappeared at 40 mM. CaSR expression at 3 mM calcium is one fold 
higher than that of at 1.2 mM. CaSR expression at 5 mM calcium is two folds higher than that of 
at 1.2 mM. CaSR expression at 10 mM calcium is four folds higher than that of at 1.2 mM. 
Because the cells were starved first before adding calcium, the change of expression of CaSR 
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truly reflects the effect of calcium. This mimics the bone environment of high calcium 
concentration, helping us understand cancer cells’ surviving in bone. 
 
      
Figure 4.4 CaSR expression increases with elevation of the extracellular calcium concentration. 
PC-3 cells were cultured with various concentrations of calcium for 2 days, and the cell lysates 
were extracted to carry out western blotting as described in Materials and Methods. This result is 
representative of 3 separate of experiments. 
 
 
4.3.3 ShRNA Knocking down of CaSR expression in PC3 and C4-2 cells  
Fig 4.5 shows that the higher expression of CaSR in PC-3 cells originally obtained from a 
bony metastasis with a higher potential for metastasis to bone than that of LNCaP cells originally 
obtained from a non-bony metastasis with low metastatic potential that was. We then test the role 
of CaSR might be an important factor involved in bony metastasis of prostate cancer. The effects 
of knocking CaSR down in PC-3 cells were, therefore, investigated.  
The small hairpin sequence for interfering CaSR of 641-646 (NM00178065) or 631-636 
(NM_000388) used by Liao et al was used in this study (52).  As shown in Fig 2.1, this method 
uses lentivirus to carry shRNA into cell. shRNA is reverse transcripted into cDNA and integrated 
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into genomic DNA of cell. Therefore, shRNA can be continually transcripted to produce siRNA. 
siRNA can bind to target protein mRNA to interfere protein’s translation. 
 
The sequence is: 
“CGGGCTGGGTGTGTTTATCAAGTTCTCGAGAACTTGATAAACACACCCAGCTTTTT”. 
pLKO.1-CaSR (Addgene), co-transfected with psPAX2 and pMD2.G into HEK-293T cells, 
produces the virus of pLKO.1-CaSR. pLKO.1-control, when co-transfected with psPAX2 and 
pMD2.G into HEK-293T cells, produces the control virus, which has an shRNA with a 
scrambled sequence that has no target gene. On the second and the third days after transfection, 
the medium containing the pLKO.1-CaSR and pLKO.1-control viruses was collected and filtered 
to infect PC-3 prostate cancer cells.  
 
Fig 4.6 shows that CaSR expression monitored 3 weeks post infection by Western blot 
using ADD CaSR antibody was knocked down in PC-3 cells using viral infection to transfect the 
specific and control shRNAs. Control knocking is PC-3 cells infected by a non-sense shRNA, 
which will not interfere any protein translation. Quantitative analysis of the expression level of 
CaSR was determined using the band intensity ratio of band of CaSR at 120 kD over GAPDH at 
36 kD using ImageJ (Method, chapter 2.5). Compared with PC-3, about 50% CaSR expession 
was knocked down. .  
 
Knocking down (KD) in CaSR expression in C4-2 cells using virus infection was also 
attempted three times using this same method. As shown in Fig.4.6, the CASR expression 
increased instead of decreasing at 2.5 weeks post infection. This result suggest that CaSR  in C4-
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2 cells can not be knocked down using the same design of ShRNA. (Fig 4.6). The reason might 
be because the genotype of CaSR has been changed since C4-2 was obtained from mice. The 
increase of CaSR expression for control KD as well for ShRNA KD might due to virus infection. 
Lentivirus was used to carry shRNA into cells. It is possible that lentivirus infection will increase 
CaSR expression. Thus, PC-3 cells with and without CaSR knock down were chosen to observe 
the effect of CaSR in various cancer cellular processes including prolification, apoptosis, 
migration, invasion and EMT and MET.  
 
 
 
 
 
 
 
 
 
Figure 4.5 CaSR expression is knocked down (KD) by shRNA in PC-3 cells relative to that in 
cells infected with the control shRNA. ShRNA, which was designed to knock down CaSR, was 
packaged into a lenti viral vector. Control knock down means PC-3 cells was infected with 
shRNA of non-sense. CaSR knock down means PC-3 cells was infected with shRNA targeting to 
inhibit CaSR expression. PC-3 cells were infected with the virus in RPMI1640 medium and the 
infected clone was amplified and picked up to test for CaSR expression. ADD CaSR antibody 
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was used to detect CaSR. Exposure time is about 15-30 minutes. This result is representative of 
three independent experiments. * indicates P < 0.05. 
 
Figure 4.6 CaSR expression is knocked down (KD) by shRNA in C4-2 cells relative to that in 
cells infected with the control shRNA. ShRNA, which was designed to knock down CaSR, was 
packaged into a lenti viral vector. C4-2 cells were infected with the virus and the infected clone 
was amplified and picked up to test for CaSR expression. Control knock down means PC-3 cells 
was infected with shRNA of non-sense. CaSR knock down means PC-3 cells was infected with 
shRNA targeting to inhibit CaSR expression. This result is representative of three independent 
experiments. * indicates P < 0.05.  
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4.3.4. Cell viability of PC-3 Cells after knocking CaSR down 
              To observe the effect of knocking CaSR down on cell viability, we seeded both PC-3 
control knock down and PC-3 CaSR knock down cells in 96-well plate. The next day, the 
medium was changed to calcium free DMEM with 0.2% BSA. After overnight incubation, 
different concentration of calcium chloride was added to mimic bone environment of high 
calcium. After 24 hours of treatment, cell viability was measured by MTS method as described 
in Method 2.8. 
 
Figure 4.7 Knocking CaSR down impaired the viability of PC-3 Cells. PC-3 cells infected by 
non-sense shRNA are named as PC-3 control knock down. PC-3 cells infected by shRNA 
targeting to decrease CaSR expression are named as PC-3 CaSR knock down. Both cells were 
treated with calcium free DMEM medium with 0.2% BSA overnight. The next day, different 
concentration of calcium was added. After 24 hours of incubation, cell viability was measured as 
described in Methods (2.8). 
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              As shown in Fig 4.7, both cells’s viability decreased after 24 hours treatment of 
calcium. Especially, at high calcium concentration of 20 mM, 30 mM, and 40 mM, the cell 
viability of PC-3 CaSR knock down decreased to half of that of PC-3 control knock down. This 
is because the calcium free DMEM medium with 0.2% BSA is different from generally used 
medium of RPMI1640 with FBS for PC-3. Cell growth of PC-3 needs nutrition in RPMI1640 
and FBS. The cell viability of PC-3 CaSR knock down decreased more than that of PC-3 control 
knock down, especially at high calcium concentration. It suggested that PC-3 CaSR knock down 
needed more nutrition and cannot tolerate high calcium. Reversibly, CaSR helped cancer cells 
tolerate high calcium and low nutrition.  
              Is this decrease of cell viability by knocking CaSR down due to CaSR’s effect on cell 
apoptosis? To answer this question, we investigated the cell apoptosis rate of PC-3 control knock 
down cells and PC-3 CaSR knock down cells at different calcium concentration environment. 
The effect of calcium concentration on cell proliferation of PC-3 cell and LNCaP was also 
examined by MTS cell proliferation assay. As shown in Fig 4.8, PC-3 cell’s proliferation 
increased with the increase of calcium concentration. The cell viability of PC-3 cell at 2.5 mM 
calcium is about 1.8 folds higher than that of at 0.5 mM calciu. However, LNCaP cell didn’t. 
Serum calcium concentration is about 1.1-1.4 mM. LNCaP cell can proliferate at 1.5 mM 
calcium, but not in 2.5 mM calcium, which is larger than serum calcium concentration. It is 
because LNCaP is the prostate cancer cell line metastasizing to brain, not to bone. It cannot 
tolerate higher calcium concentration than serum. PC-3 cells is the prostate cancer cell line 
metastasizing to bone. It can tolerate high calcium concentration and proliferate well. Moreover, 
PC-3 has higher CaSR expression than LNCaP. This confirms our hypothesis that bone 
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environment with high calcium increases CaSR expression of cancer cell so that cancer cell can 
survive and proliferate. 
 
 
Figure 4.8 Effect of calcium concentration on cell proliferation of PC-3 and LNCaP Both PC-3 
and LNCaP cells were treated with calcium free DMEM medium with 0.2% BSA overnight. The 
next day, different concentration of calcium was added. After 24 hours of incubation, cell 
viability was measured by MTS as described in Methods (2.8). 
 
                
4.3.5 Effect of CaSR in apoptosis  
Calcium concentrations in specific microenvironments within the body ranges wide. The 
normal calcium concentration in human serum is about 1.1-1.4 mM. However, calcium 
concentrations can reach levels as high as 40 mM in the bony microenvironment close to 
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resorbing osteoclasts. The effect of CaSR knock down on survival of PC-3 cells in a range of 
calcium concentrations was, therefore, investigated using several methods.  
Annexin V/Dead cell apoptosis kit (Invitrogen) is a rapid and convenient assay for 
apoptosis. In normal live cells, phosphatidyl serine (PS) is located on the cytoplasmic surface of 
cell membrane. However, in apoptotic cells, PS is translocated from the inner to the outer side of 
plasma membrane. The human anticoagulant, annexin V, has a high affinity for PS. Therefore, 
annexin V labeled with a fluorephore can identify apoptotic cells by binding to PS exposed on 
the outer leaflet. The kit also includes a red-fluorescent propidium iodide (PI) nucleic acid 
binding dye. PI is impermeant to live cells and apoptotic cells, but stains dead cells with red 
fluorescence. After staining cells with annexin V and PI, apoptotic cells show green 
fluorescence, dead cells show red and green fluorescence, and live cells show little or no 
fluorescence. 
 PC-3 has lowest apoptosis rate when treated with calcium free DMEM media plus 2 mM 
calcium (Fig 4.9A). This is because serum calcium concentration is about 1.1-1.4 mM. 
Therefore, 2 mM is the most favorable calcium concentration for PC-3 cell. That’s why it shows 
lowest apoptosis rate. Fig 4.9B shows that the apoptosis of PC-3 cells increases after CaSR was 
knocked down, especailly at 0 mM  and 40 mM calcium concentration. CaSR may be an 
important factor that inhibits the apoptosis of prostate cancer cells in bone.  
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Figure 4.9 Apoptosis rate of PC-3 control knock down and PC-3 CaSR knock down cells. A. 
Apoptosis rate of PC-3 at different calcium concentration. B. Apoptosis rate of PC-3 control 
knock down and PC-3 CaSR knock down cells at different calcium concentration. PC-3 control 
knock down and PC-3 CaSR knock down cells were treated with calcium-free medium and 
medium with various calcium concentrations for 20 hours.  * indicates P < 0.05. 
 
There are other methods that can be used to measure cell apoptosis. One is DNA ladder 
analysis. Short DNA fragments are formed in apoptosis. These fragments are regularly spaced in 
size. If cellular DNA is extracted and purified and analyzed by agarose gel electrophoresis, bands 
of 180bp and multimers of 180bp will be seen, like a ladder. The other is to measure the 
activation of caspases. Apoptotic processes include activation of caspase cascade, including 
caspase-3, caspase-8, and caspase-9, etc. Cells are lysed and activated caspases can be captured 
out of cellular lysates by anti-caspase antibodies using western blot. 
 
4.3.6 Effect of Taxotere on the cell apoptosis of PC-3 
               Taxotere is a chemotherapy drug inducing tumor cells apoptosis. The concentration of 
it used to induce apoptosis ranges from 0.5 nM to 40 nM (119-121). 2 nM and 5 nM taxotere 
were used to induce apoptosis of PC-3 cells and PC-3 cell transfected with CaSR for 3 days. As 
shown in Fig 4.10, when cells were treated with 2 nM taxotere for 3 days, the apoptosis rate of 
PC-3 transfected with CaSR is higher than that of PC-3 cells. When being treated with 5nM 
taxotere for 3 days, there is no difference between two groups. It suggests that CaSR can increase 
apoptosis of cells when induced by chemodrug. The dead cell rate is calculated according to the 
cell population with PI positive staining. The dead cell rate shows that PC-3 cell transfected with 
CaSR had more cell death than PC-3 cells. Therefore, CaSR may inhibit apoptosis in high 
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calcium environment but cannot inhibit apoptosis induced by chemodrug. We treated PC-3 cells 
with taxotere and different concentration of calcium together. It was found that the apoptosis rate 
did not significantly change. One probable cause could be the incubation time was insufficient . 
   A                                                                                B 
 
 
Figure 4.10 Apoptosis rate of PC-3 and PC-3 transfected with CaSR cells. A: Apoptosis in PC-3 
cells treated with different concentrations of taxotere for 3 days was measured. * indicates P < 
0.05. B: Apoptosis in PC-3 luciferase control cells and PC-3 luciferase CaSR knock down cells 
were treated with 6nM taxotere for 2 days and different concentration of calcium for 24 hours.  
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Figure 4.11 Dead cell rate of PC-3 and PC-3 transfected with CaSR cells. PC-3 cells were treated 
with different concentrations of Taxotere for different time range. Dead cell rate was then 
measured using the annexin V PI kit by flow cytometry. * indicates P < 0.05. 
 
 
4.3.7 CaSR decreases cell invasiveness in PC-3 cells and LNCaP cells but has no effect on 
migration 
To compare differences between PC-3 control cells and PC-3 CaSR knock down cells, 
chambers were used to test cell migration and invasion. Fig 4.12 shows that method used in these 
studies. The bottom of chamber is the membrane with some pores. Cell can migrate through 
these pores to the other side. Serum free media is added to inside of the chamber and media with 
FBS is added to outside of the chamber. Therefore, cells are attracted through the hole of the 
membrane to the other side to the nutrition. Chambers containing biocoat matrigel is used to 
measure cell invasion. Matrigel mimic extracellular matrix. Cells use matrix metalloproteinase to 
digest matrigel first before going through the pores to the other side.  
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Figure 4.12 Schematic diagrams for migration and invasion assays. Chamber with membrane at 
the bottom is inserted into well of 24-well plate. The membrane has hole through which cells can 
migrate to the other side of the membrane. Serum free media is added to inside of chamber and 
media with FBS is added to outside of the chamber. For invasion assay, matrix gel mimicking 
extracellular matrix is added to the bottom of chamber as shown in green. Cells require to digest 
matrix first if they go through the membrane to the outside of the chamber. 
 
 
PC-3 CaSR knock down cells showed three folds higher percentage of cells invading the 
matrigel than that of the PC-3 control knock down cells (Fig 4.13A). This was confirmed using 5 
mM calcium (Fig. 4.13B). PC-3 CaSR knock down cells showed two folds higher percentage of 
invasion than that of the PC-3 control knock down cell at 5mM calcium. Calcium chloride was 
added directly to RPMI1640 with FBS medium to mimic bone environment of high calcium 
concentration. This is different from cell viability experiments where calcium free DMEM media 
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is initially used to starve cells. In migration and invasion experiments, FBS has to be added to 
outside of the chamber. Therefore, calcium starving is not possible. The result suggests that 
knocking CaSR down increases cell invasion, especially in high calcium bone environment. 
Reversibly, CaSR will decrease cell invasion in bone environment. 
PC-3 control knock down refers to PC-3 cells transfected with shRNA that does not 
target CaSR mRNA. PC-3 CaSR knock down refers to PC-3 cells transfected with shRNA with 
sequence of CTGGGTGTGTTTATCAAG. This sequence of DNA translates to LGVFIK amino 
acids in exon 7 of CaSR. We made a mutation CaSR plasmid with corresponding sequence of 
CTGGGAGTCTTCATTAAG. Although the DNA sequence seems mutated, the translational 
amino acid sequence is still LGVFIK. This is called silent mutation, which mutates DNA to 
avoid shRNA attack but translates the same protein. When a CaSR with a silent mutation 
(CTGGGAGTCTTCATTAAG), not targeted by the shRNA (CTGGGTGTGTTTATCAAG), 
was transfected into PC-3 CaSR knock down cells to restore CaSR expression (control knock 
down), CaSR expression increased two folds compared to CaSR knock down cell. Cell invasion 
decreased one fold compared to PC-3 CaSR knock down (Fig 4.14). Overexpression of CaSR in 
LNCaP cells decreased their ability to invade the matrigel matrix about 0.3 folds (Fig 4.15).  
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Figure 4.13 Cell invasion in normal calcium concentration and in high (5 mM) calcium 
concentration. Cell invasiveness was tested using a Boyden chamber assay as described in 
Materials and Methods. Cells that migrate through the matrigel and the holes in the membrane at 
the bottom of the chamber are considered invasive cells. Cell invasiveness is expressed as the 
percentage of invading cells relative to those migrating. Cell invasion ability increased after 
CaSR was knocked down. This result is representative of three independent experiments. * 
indicates P < 0.05. 
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Figure 4.14 Cell invasion by PC-3 cells in different concentrations of calcium. A: Western blot 
of PC-3 CaSR knock down and PC-3 CaSR knock in cells. B: Cell invasion by PC-3 CaSR 
knock down and PC-3 CaSR knock in cells. PC-3 control knock down refers to PC-3 cells 
transfected with shRNA that does not target CaSR mRNA. PC-3 CaSR knock down refers to PC-
3 cells transfected with shRNA that reduces CaSR mRNA expression. PC-3 CaSR knock in 
refers to PC-3 knock down cells transfected with silent mutant CaSR plasmid. This result is 
representative of three independent experiments.  * indicates P < 0.05. 
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Figure 4.15 LNCaP cells overexpressing the CaSR showed less invasiveness than control LNCaP 
cells. LNCaP cells were transfected with wild type CaSR in pcDNA3.1 in RPMI1640 with FBS. 
RPMI1640 media has calcium concentration of 0.42 mM. FBS also has calcium with 
concentration of 3.7 mM. FBS is 10 times diluted when added to RPMI1640. Therefore, the final 
concentration of RPMI1640 with FBS media is about 0.79 mM. The cells were seeded in the 
Boyden chamber with matrigel on the bottom as described in Materials and Methods. This result 
is representative of three independent experiments. * indicates P < 0.05. 
 
Cell migration was done in Boyden chambers. PC-3 control knock down and PC-3 CaSR 
knock down cells were seeded in chambers inserted in wells of 24-well plate. Serum free 
RPMI1640 media was added to inside of chamber and RPMI1640 with FBS was added to 
outside of chamber. RPMI1640 media has calcium concentration of 0.42 mM. FBS also has 
calcium with concentration of 3.7 mM. FBS is 10 times diluted when added to RPMI1640 to 
make RPMI1640 with FBS media. Therefore, the calcium concentration inside of the chamber is 
0.42mM. The calcium concentration outside of the chamber is 0.79 mM. If calcium equilibrates 
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inside and outside of the chamber, the whole system has calcium concentration of 0.6 mM. 
Assessment of cell migration showed that there was no difference in migration between PC-3 
control knock down cells and PC-3 CaSR knock down cells (Fig. 4.16).  
 
 
 
Figure 4.16 Cell migration was tested by the Boyden chamber method. Cells that pass through 
the holes in the membrane at the bottom of the chamber are considered to have migrated. Cell 
migration is expressed as the number of cells that have migrated through the membrane. This 
result is representative of three independent experiments. 
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Figure 4.17 Cell migration of PC-3 control knock down and PC-3 CaSR knock down cell by cell 
scratch assay. Both PC-3 control knock down and PC-3 CaSR knock down cells were seeded 
into wells of 6-well plate in RPMI 1640 media with FBS. A wound was made by a tip in 
monolayer of cells with high conflueny. The wideness of the wound was observed at 0 day, 1 
day, and 2 days under microscope. 
 
              When cell migration was measured by cell scratch assay, it shows cell migration 
decreased after CaSR was knocked down as seen in Fig 4.17 that the wideness of wound is larger 
in PC-3 CaSR knock down cell compared to PC-3 control knock down cells at 2 days time point. 
The results are inconsistent with that of Boyden chamber assay. The reason for the wider wound 
could have resulted from PC-3 CaSR knock down cell proliferating slower than PC-3 control 
knock down cell.  
 
4.3.8 CaSR decreased the expression of MMP and increased the expression of integrin and 
E-cadherin in PC-3 cells 
To investigate the mechanism underlying the increased invasiveness of PC-3 cells after 
knocking CaSR down, the expression of matrix metalloproteinase-2 and 9 (MMP-2 and MMP-9) 
were investigated using western blot. MMP-2 and MMP-9 are both important collagenase 
capable of digesting matrix and reported by Matsubara (122). 
Knocking CaSR down in PC-3 cells increased about one fold of the expression of MMP-
2 (Fig 4.18) stained by anti-MMP2 antibody.  MMP9 was not detected in PC-3 control knock 
down. However, there is a significant increased expression of MMP9 after knockdown which 
might contribute to the increased cell invasiveness, i.e., owing to degradation of the matrigel.  
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β-integrin plays an important role in cell-extracellular matrix connection; E-cadherin 
functions in cell-cell interaction. Therefore, the expression levels of the cell adhesion molecules, 
β-integrin and E-cadherin, were also measured using western blot to understand the involvement 
of CaSR in these cellular properties. Fig 4.19 shows that the expression of E-cadherin was 
completely decreased after knocking CaSR down. The expression of integrin β1 decreased three 
folds.  
 
Figure 4.18 CaSR knock down in PC-3 cells increases the expression of MMP-2 and MMP-9 
Cell lysates of PC-3 cells and PC-3 CaSR knock down cells were extracted, and western blotting 
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was carried out to quantify the expression of MMP-2 and MMP-9 as described in Materials and 
Methods. This result is representative of three represented experiments. * indicates P < 0.05. 
 
 
 
 
Figure 4.19 Effects of knocking CaSR down on expression of integrin β1 and E-cadherin. Cell 
lysates of PC-3 cells and PC-3 cells with CaSR knocked down were extracted and loaded onto a 
gel to carry out western blotting as described above. This result in the top panels is representative 
of three independent experiments and the combined results from these experiments are analyzed 
by densitometry in the lower panels. * indicates P < 0.05. 
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4.3.9 CaSR maybe decrease cell attachment 
               Cell attachment assay was done on PC-3 cells and PC-3 cells transfected with CaSR. 
Same amount of PC-3 cells and PC-3 cells transfected with CaSR were seeded into wells of 6-
well plate to make triplets. One hour later, the unattached cells were washed away by PBS. The 
attached cells were trypsinized down and collected as cell suspension. Hemocytometer was used 
to count cell number of cell suspension in each well. Finally, cell number of each group were 
compared and statistically analyzed. As shown in Fig 4.20, PC-3 cells have more attached cells 
than PC-3 cells transfected with CaSR. However, the error bars are big for both the groups. If the 
paired t-test is used to compare the cell number, P is less than 0.05. If two sample equal variance 
t-test is used, P is larger than 0.05. Therefore, the results need to be repeated. The conclusion 
cannot be made yet. 
 
Figure 4.20 Cell attachment of PC-3 cells and PC-3 cells transfected with CaSR. Same amount 
of PC-3 cells and PC-3 cells transfected with CaSR were seeded in 6 well plate. Two hours later, 
unattached cells were washed away by HBSS for three times. Attached cells were trypsinized 
down and counted by Hemocytometer. 
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4.3.10 CaSR causes mesenchymal-epithelial transition (MET) in PC-3 cells 
MET (mesenchymal-epithelial transition) is a biological process involving the transition 
from mesenchymal cells to epithelial cells. It is believed to participate in the distant metastases 
by cancer cells to integrate into distant organs. The protein patterns in MET are described in 
Table 4.2. Since the expression of E-cadherin decreased after knocking CaSR down, other 
molecules participating in epithelial-mesenchymal transition were also investigated. CaSR knock 
down increased the expression of vimentin by two folds and smooth muscle actin for 0.3 folds 
and decreased the expression of E-cadherin by one fold and γ-catenin for 0.5 folds (Fig 4.21), 
changes that are characteristics of EMT.  
 
Table 4.2 Protein change pattern for EMT (epithelial-mesenchymal transition) and MET 
(mesenchymal- epithelial transition) 
 EMT (epithelial-
mesenchymal transition) 
MET (mesenchymal- 
epithelial transition) 
E-cadherin decrease increase 
γ-catenin decrease increase 
smooth muscle actin increase decrease 
vimentin increase decrease 
 
We also set up PC-3 luciferase control and CaSR knock down cells. Furthermore, we 
treated cells with 2 mM and 10 mM different calcium concentration. It is found that CaSR 
expression decreased in PC-3 luciferase CaSR knock down cells. E-cadherin expression 
decreased with the decrease of CaSR. However, N-cadherin expression increased with the 
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decrease of CaSR. These are consistent with the EMT pattern. It is also found that 10 mM treated 
PC-3 luciferase cells have more CaSR expression than that of 2 mM treated ones. This is also 
consistent with the point that high calcium concentration increase CaSR expression in 4.3.2. 
Filamin is the downstream signaling molecule of CaSR. It is supposed to change with the 
change of CaSR. However, we found that when CaSR was knocked down, the expression of 
filamin increased 1.5 folds (Fig 4.22). We don’t know why it happens. It needs to be investigated 
further. 
 
Figure 4.21 Expression of epithelial-mesenchymal transition (EMT)-related proteins in PC-3 
CaSR knock down cells. Cell lysates of PC-3 cells and PC-3 cells with CaSR knocked down 
were extracted and loaded onto gels to carry out western blotting. This result is representative of 
three experiments. * indicates P < 0.05. 
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Figure 4.22 Expression of epithelial-mesenchymal transition (EMT)-related proteins in PC-3 
luciferase CaSR knock down cells. Cell lysates of PC-3 luciferase cells and PC-3 luciferase cells 
with CaSR knocked down were extracted and loaded onto gels to carry out western blotting. This 
result is representative of three experiments. * indicates P < 0.05. 
 
Figure 4.23 CaSR knock down in PC-3 caused decrease of E-Cadherin and increase of filamin. 
Cell lysates of PC-3 cells and PC-3 cells with CaSR knocked down were extracted and loaded 
onto gels to carry out western blotting. This result is representative of three experiments. * 
indicates P < 0.05. 
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4.3.11 CaSR decreases cell invasiveness and causes mesenchymal-epithelial transition in the 
breast cancer cell line MDA-MB-231  
In the breast cancer cell line, MCF-7 cell line has no metastatic potential. MDA-MB-231 
cell line has bone metastatic potential. MDA-MB-231 has more CaSR expression than that of 
MCF-7 cells. CaSR could play a vital role in promoting metastases. (Fig 4.23) MDA-MB-231, 
CaSR also produced a decrease in cell invasiveness as assessed by the matrigel assay (Fig 4.24). 
It likewise resulted in increased expression of vimentin and decreased expression of E-cadherin 
and γ-catenin, which are characteristics of changes observed in EMT, indicating that the 
presence of CaSR favors MET. (Fig 4.25) 
 
4.3.12 PC-3 cell cultured in Conditioned medium of RAW264.7  
           RAW264.7 cell is the murine macrophage cell. It can be differentiated to osteoclast. It is 
because this cell can secrete many cytokines, such as TNFα, IL-6, IL-10, IL-8, IFNγ, etc. These 
cytokines exist in bone environment a lot. Therefore, the media which is collected after 
RAW264.7 cell was cultured for 1 day can be used to mimic bone environment. We name 
DMEM high glucose media without FBS as control media. The media collected after RAW264.7 
was cultured in DMEM high glucose media without FBS for 1 day is called conditioned media. 
As shown in Fig 4.26, when PC-3 is cultured in conditioned media, CaSR expression is very low. 
After PC-3 was cultured in conditioned media, CaSR expression increased 1.5 folds compared to 
control media. After PC-3 was cultured in conditioned media for 2 days, CaSR expression 
increased 7 folds. After being cultured for 3 days, CaSR expression increased 11 folds. It 
confirmed that prostate cancer cell will have high expression of CaSR in bone environment. 
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Figure 4.24 CaSR expression in breast cancer cell lines. MCF-7 is a breast cancer cell line that 
does not metastasize to bone. MDA-MB-231 is a breast cancer cell line that has the potential to 
metastasize to bone. This result is representative of three independent experiments. * indicates P 
< 0.05. 
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Figure 4.25 Effect of knocking CaSR down on invasion of MDA-MB-231 cells. Cell invasion 
was tested by Boyden chamber assay as before. MDA-MB-231 cells were seeded into 
chamber in DMEM low glucose medium with calcium concentration of 1mM. DMEM low 
glucose medium with FBS was added outside the chamber. DMEM low glucose medium 
has calcium at 1 mM. FBS has calcium of 3.7 mM. Since FBS is 10 times diluted in DMEM 
low glucose media, the final calcium concentration is 1.37 mM. If calcium reaches 
equilibrium inside and outside of the chamber, calcium concentration in whole system is 
about 1.7 mM. Cell invasion is expressed as the percentage of invading cells relative to the 
number of migrating cells. There is a significant difference between the MDA-MB-231 
control knock down cells and the MDA-MB-231 CaSR knock down cells in terms of 
invasiveness with knock down of the CaSR being associated with increased invasiveness. 
This result is representative of three independent experiments. 
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Figure 4.26 Expression of epithelial-mesenchymal transition (EMT)-related proteins in MDA-
MB-231 CaSR knock down cells. Cell lysates of control knock down MDA-MB-231 cells and 
the MDA-MB-231 cells with CaSR knock down were extracted and western blotting was carried 
out. This result is representative of 3 independent experiments. * indicates P < 0.05. 
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Figure 4.27 Effect of conditioned media of RAW264.7 cells on expression of CaSR in PC-3 cell. 
RAW264.7 cell was generally cultured in DMEM high glucose with FBS media. Here control 
media is the DMEM high glucose without FBS. Conditioned media is the media collected after 
RAW264.7 cells were cultured in control media for 1 day. Control media 1d means PC-3 cells 
were cultured in DMEM high glucose without FBS for 1 day. Conditioned media 1d means PC-3 
cells were cultured in conditioned media for 1 day. Conditioned media 2d means PC-3 cells were 
cultured in conditioned media for 2 days. Conditioned media 3d means PC-3 cells were cultured 
in conditioned media for 3 days. Then each group of PC-3 cells were lysed and loaded into SDS-
PAGE gel to do western blot. Another possible reason for such difference is due to differences in 
calcium concentration of mediums. RPMI1640 medium has calcium with concentration of 
0.5mM while DMEM medium has calcium with concentration of 1.2mM. It is possible that PC-3 
cells cultured in conditioned medium of RAW cell which has 0.7mM higher calcium 
concentration than before got stimulated by increased calcium and enhanced CaSR expression. 
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4.4 Discussion 
4.4.1 CaSR expression in cancer cells and patients 
          Prostate and breast cancer have in common the tendency to metastasize to bone in their 
advanced stages. CaSR is considered as an important factor in promoting bony metastasis. Breast 
cancers from patients with bony metastases have higher levels of expression of CaSR than in 
patients without bony metastases. Among prostate cancer cells, the PC-3 cell line, which 
originated from a bony metastasis, has higher expression of CaSR than LNCaP cells, which 
originated from a non-bone metastatic site. This result is consistent with our observation for the 
bone metastasis patient sample. We have recently shown that there is a higher level of CaSR 
expression in prostate cancer metastatic to bone than in prostate cancer isolated from the prostate 
bed. There is, however, no difference in CaSR expression between normal prostate tissue and 
prostate cancer tissue limited to the prostate or metastatic to sites other than bone. These results 
suggest that either CaSR expression increases after prostate cancer cells metastasize to bone or 
that the bony microenvironment selects for metastasizing cells with high CaSR expression.  
          We use shRNA carried by lentivirus to knock down CaSR in PC-3 cells. At the 
same time, we infected nonsense shRNA which will not target any protein to the cell as control. 
As we can see from Fig 4.5, compared to PC-3, PC-3 control knock down and PC-3 CaSR knock 
down cells have increased CaSR expression. PC-3 control knock down has more CaSR increased 
than that of PC-3 CaSR knock down. It is possible that virus infection increased calcium 
concentration in cell, which induces enhancement of CaSR expression. Inal et al. reported that 
coxackievirus B infection increases intracellular calcium concentration. As a result, actin 
cytoskeleton is depolymerized (123).  
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4.4.2. The effect of calcium on CaSR expression 
             We have observed that CaSR expression in PC-3 cells increased with the increase of 
extracellular calcium concentration.  Increased Ca
2+
o enhanced the proliferation of PC-3 cells but 
not of LNCaP cells (Fig 4.6). This result is consistent with the results of Liao et al (52). In their 
paper, Liao et al. found that PC-3 prostate cancer cells (obtained from a metastatic site in bone) 
have higher levels of CaSR mRNA than LNCaP cells (obtained from a lymph node). In their 
paper, knockdown of CaSR expression reduced cell growth of PC-3 cells both in vitro and in 
vivo in a murine model of prostate cancer metastasis.  
       When the calcium concentration in the medium was increased from 0.5 mM to 10 mM, 
CaSR expression in PC-3 cells increased correspondingly. According to some reports, the 
calcium concentration in bone can reach levels of up to 8-40 mM (124). CaSR can decrease cell 
apoptosis in PC-3 cells. Therefore, CaSR can maintain cell survival in bone. It might be possible 
that the increased CaSR expression in prostate cancer cells that have metastasized to bone results 
from these high local calcium concentrations in bone, which, in turn may favor the development 
of bony metastases near sites of active bone turnover (125).  
            However, the C4-2B cells line, which is regarded to have a greater propensity to 
metastasize to bone than C4-2 cells, did not show a higher level of CaSR expression. In Liao’s 
paper, they did not detect CaSR expression in C4-2 cells. We do not know the comparison of 
CaSR expression between C4-2 and C4-2B cells by them. Presumably there are factors in 
addition to CaSR expression that can impact the ability of prostate cancer cells to metastasize to 
bone. It is possible that the bone environment of mouse is different from that of human. Maybe 
calcium concentration in bone is not much higher than serum calcium concentration in mouse. 
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4.4.3 The effect of CaSR on migration and invasion 
        We didn’t detect any effect of decreased CaSR expression on the migratory capacity of 
PC-3 cells. Adams et al. reported that the migration of CaSR-/- hematopoietic stems cells was 
the same as the corresponding CaSR+/+ cells, which is consistent with our results (126). Cell 
invasion as assessed by a Boyden chamber assay increased in PC-3 cells when CaSR was 
knocked down. Moreover, transfection of the cells with a silent mutant of CaSR, which is not 
susceptible to knock down by the shRNA used here to knock down wild type CaSR reduced the 
invasiveness of the cells. Overexpression of CaSR in LNCaP cells also decreased cell invasion, 
consistent with the results observed with PC-3 cells. Thus expression or overexpression of the 
CaSR in both cell lines decreased cell invasion. 
         After CaSR was knocked down, cell invasion of PC-3 was increased. Reversibly, CaSR 
could inhibit cell invasion. The reason underlying the changes in cell invasiveness could be that 
the reduction in CaSR expression increased the expression of MMP-2 and MMP-9 and decreased 
expression of E-cadherin and integrin β1, thereby decreasing cell-cell and cell-matrix adhesion. 
MMPs are capable of degrading many types of extracellular matrix proteins thereby removing 
potential obstructions to cell migration and invasion. The levels of expression of MMP-2 and 
MMP-9 increased in PC-3 cells after CaSR was knocked down. E-cadherin and integrin β1, in 
contrast, are cell adhesion molecules. There are three types of cell adhesion molecules: 
cadherins, integrins and selectins. Selectins are expressed predominantly in endothelial cells.  
We didn’t focus on selectins since PC-3 cells originated from epithelial prostate cancer cells. 
Cell-cell adhesion in adherens junctions are mediated by cadherins. Cell–matrix adhesion 
however, is usually mediated by integrins. E-cadherin is a key cadherin and integrin β1 is an 
important integrin. Expression of E-cadherin and integrin β1 decreased when CaSR expression 
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decreased in PC-3 cells. This suggests that knockdown of the CaSR may have impaired cell-cell 
and cell-matrix adhesion after CaSR was knocked down, which would enhance the capacity of 
the cells to invade. 
 
4.4.4 The effect of CaSR on Apoptosis 
              We found CaSR knock down increased cell apoptosis of PC-3, especially in high 
calcium concentration, like 40mM. It suggests that CaSR can inhibit cancer cell apoptosis at high 
calcium concentration. However, overexpression of CaSR in PC-3 cells cannot protect cells from 
apoptosis induced by chemodrugs. It is possible that CaSR only helps cancer cells more tolerable 
to high calcium environment but not other situations. The other possibility is that the 
overexpressed CaSR in PC-3 is different from endogenous CaSR in PC-3. It is not real reflect of 
the increased expression of endogenous CaSR. At 0 mM calcium concentration, PC-3 knock 
down cells also showed higher apoptosis rate than that of PC-3 CaSR knock down cell. It 
suggests that CaSR can be stimulated by other ligand in calcium free environment to protect cells 
from apoptosis. 
 
4.4.5 The effect of CaSR on EMT-MET 
               E-cadherin is also an important player in epithelial-mesenchymal transition (EMT). 
Epithelial-mesenchymal transition or transformation is hypothesized to represent a recapitulation 
of a developmental program characterized by loss of cell adhesion, repression of E-cadherin 
expression, and increased cell mobility. Other EMT-related proteins are smooth muscle actin, γ-
catenin, vimentin. Characteristics of EMT are an increased expression of vimentin and smooth 
muscle actin and decreased expression of E-cadherin and γ-catenin (127). Knocking CaSR down 
98 
 
resulted in decreased expression of both E-cadherin and γ-catenin and increased expression of 
smooth muscle actin and vimentin. In other words, knocking CaSR down induces EMT in PC-3 
cells. Reciprocally, CaSR induces mesenchymal-epithelial transition (MET) in PC-3 cells. The 
result that Arcap E cells have higher CaSR expression than Arcap M cells also suggests that 
CaSR promotes an epithelial phenotype. Christine et al. pointed out that “Colonization-
adaptation of the disseminated cell to the microenvironment at the metastatic site disseminated 
cells that may have arrived in a quasi-mesenchymal/cancer stem cell state may lapse back to a 
fully epithelial state and thereby forfeit the “stem-ness” that would seem to be essential for their 
successful founding of metastases ” (128). Hence, epithelial characteristics are needed for 
colonization of a metastatic site by cancer cells. CaSR can promote mesenchymal-epithelial 
transition, which may enhance the capacity of the cells to colonize a metastatic site.  
4.4.6 CaSR in breast cancer 
          In the breast cancer cell line, MDA-MB-231, CaSR knock down also resulted in 
increased cell invasiveness but cell migration didn’t change. Saidak et al. showed that CaSR 
increased cell migration of the breast cancer cell line, MDA-MB-231 (129). The difference 
between our study and theirs might be due to the different cell lines studied or the methods 
employed. We used a Boyden chamber assay, and they used a cell scratch method to detect cell 
migration. It likewise caused increased expression of vimentin and decreased expression of E-
cadherin and γ-catenin. Thus CaSR’s ability to decrease cell invasiveness and promote 
mesenchymal-epithelial transition was present not only in prostate cancer cell line but also in a 
breast cancer cell line.  
           Fig. 4.27 shows our working model. Based on the finding of the role of CASR in 
protection of apoptosis and MET, we propose to further animal studies to test the role of CaSR in 
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bone metastasis of prostate and breast cancer. We plan to use PC-3 cell carrying luciferase to be 
injected into mice under guidance of Dr. Daqing Wu. ShRNA targeting CaSR will be infected to 
PC-3 cells carrying luciferase to make PC-3 control knock down and PC-3 CaSR knock down. 
Both cells will be directly injected to bone of mice. Since CaSR will help cancer cells colonize in 
bone, it is supposed that PC-3 CaSR knock down cell cannot or make small bone tumor 
compared to PC-3 control knock down. Both cells will be also injected subcutaneously in mice. 
Since skin has no high calcium concentration environment, the two cells will make same size of 
tumor under skin. We will also add bisphosphonate, the drug of prevention bone loss, to the bone 
tumor induced by PC-3 cells to see whether bisphosphonate have effect in inhibiting CaSR 
mediated bone metastasis of cancer. 
         Our finding might also be the basis for novel CaSR-based therapeutics directed at 
reducing the tendency of cancer cells to metastasize to bone. Development of therapeutics that 
inhibit the increased expression of CaSR in cancer cells in the bony environment might inhibit 
viability of cancer cells and/or or their colonization of bone as a way to control the late stage of 
bony metastases of various cancers, which are associated with markedly reduced life expectancy.    
         The agonist and antagonist of CaSR have been produced to activate and inactivate 
CaSR’s function. The agonist is called R-568 and the antagonist is NPS-2143. CaSR drug 
cinacalcet which is calcimimetic CaSR agonist has been used clinically to treat patient with 
hyperparathyroidism. In the future, CaSR antagonist NPS-2143 might be used to decrease CaSR 
activation in cancer patients with bone metastasis to decrease the colonization of cancer cells in 
bone. 
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Figure 4.28 Working model of CaSR facilitates cancer cell colonize in bone. After cancer cells 
arrive at bone tissue, high calcium in bone increased CaSR expression in cancer cells. Increased 
CaSR decreased apoptosis and invasion of cancer cells, making cancer cells have mesenchymal-
epithelial transition. All of these help cancer cells colonize in bone. 
 
4.5 Conclusion 
          In summary, CaSR can decrease cell apoptosis, decrease cell invasiveness, and promote 
mesenchymal-epithelial transition, all of which can facilitate the colonization of bone by prostate 
cancer or breast cancer cells. This may also be relevant to why CaSR expression in prostate 
cancer increases when it metastasizes to bone. It may represent an adaptation to the bone 
environment that results from a high local calcium concentration and proteins (e.g., 
cytokine/chemokines) secreted from osteoclasts and/or osteoblasts, both of which increase CaSR 
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expression. This, in turn, may enhance MET transition, facilitating colonization of bone by the 
cancer cells. In the future, we will inject PC-3 luciferase control cell and PC-3 luciferase CaSR 
knock down cell into mice subcutaneously and osseously to see whether PC-3 luciferase control 
cell will grow bigger tumor since it has more CaSR compared to knock down one. 
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5 INVESTIGATION OF EXTRACELLULAR CALCIUM AND CASR MEDIATED 
CALCIUM SIGNALING AND TRAFFICKING IN CANCER CELLS  
5.1 Abstract 
Extracellular calcium concentration increase can activate CaSR. CaSR activation 
subsequently activates Gαq protein downstream phospholipase C to produce IP3. IP3 binds to IP3 
receptor on ER membrane to release calcium from ER, which causes calcium oscillation. IP3 can 
degrade to IP1. The quantity of IP1 can stand for the production of IP3. CaSR also can activate 
ERK phosphorylation. Previously, we have found CaSR plays role in bone metastasis of cancer. 
To address the molecular mechanism and alteration in signaling pathway difference between 
normal cell and cancer cell, we compared calcium oscillation, IP1 production, and ERK 
phosphorylation in HEK293 cell and PC-3 cell. It is found that the oscillation pattern in PC-3 is 
different from that of HEK293 transfected with CaSR ones. HEK293 cell transfected with CaSR 
starts to have oscillation at 3 mM. PC-3 starts to have oscillation at 20 mM. Oscillation cell 
number of HEK293 cell transfected with CaSR is 5 folds more than that of PC-3 cell. IP1 is the 
metabolic derivative of IP3. In HEK293 cell transfected with CaSR, IP1 production increased 
with the increase of extracellular calcium concentration. In PC-3 cell, there is no IP1 production 
when extracellular calcium concentration increased. ERK phosphorylation increased in a 
calcium-dependent way in HEK293 cell transfected with CaSR. However, PC-3 doesn’t. 
 
5.2 Introduction 
Calcium-sensing receptor (CaSR) was first found in bovine parathyroid gland (59) to 
function as calcium sensor to regulate the secretion of parathyroid hormone. CaSR belongs to the 
group three of the G protein coupled receptor family (GPCR). 
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 As shown in Fig 1.4, the signal transduction pathway by which the CaSR regulates the 
secretion of PTH is thought to involve signaling via Gq/11 (130). CaSR, as a G protein-coupled 
receptor, undergoes conformational changes when sensing changes in Ca
2+
. This activates Gαq/11 
(as well as other G proteins, including Gi and G12/13). Downstream of Gq/11 is phospholipase C, 
which catalyzes the hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2) into inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to the IP3 receptor on the 
membranes of the endoplasmic reticulum (ER), to induce calcium release. Sequential release and 
reuptake of calcium can produce intracellular calcium oscillations. The increased intracellular 
calcium will be pumped back into the ER by a sarco/endoplasmic reticulum calcium-ATPase 
(SERCA) (131), or out of the cell via the plasma-membrane-localized Calcium-ATPase (PMCA) 
(132). The interplay of the calcium permeable channels result in the sequential regenerative 
release of stored calcium, which is called calcium oscillation. Calcium oscillation controls a 
variety of cell functions, such as fertilization, secretion, enzyme activation, and gene expression 
to cell death (133). The oscillatory behavior can not only save the cell from toxic effects of 
sustained high cytosolic calcium levels and from desensitization, but increase the efficiency of 
calcium signaling (134). The frequency of spiking calcium oscillations has been examined in 
many papers. Dekoninck and Schulman described the sensitivity of immobilized CaM kinase 2 
to calcium oscillation frequency (135). Li et al. found that NF-AT is activated at calcium 
oscillation (136). Oancea and Meyer demonstrates the activation of PKC combined with high 
frequency of calcium spikes (137). Since different calcium oscillation frequency and amplitude 
are encoded with various biological processes, computational analysis of calcium oscillation has 
been extensively performed to quantify and validate the mechanisms (138). 
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As shown in Fig 1.4, Gq/11 and Gi can also transduce signals to the MAPK pathways, 
including MEK, ERK, and JNK, to regulate gene transcription and other cellular processes. 
Cheng Zhang in Yang lab has reported the role of extracellular calcium in activation of CaSR, 
using transient transfection of CaSR into HEK293 cell that does not have any significant 
expression of CaSR (30). The functional positive cooperativity of the CaSR in HEK293 cells 
was reflected by [Ca
2+
]o–induced [Ca2+]i oscillations, inositol-1-phosphate (IP1) accumulation 
and extracellular signal-regulated kinases (ERK1/2) activity. 
We have shown that the expression of CaSR in bone metastasis patient in Chapter 3. As 
shown in Table 1.1, CaSR is also expressed in several cancer cell lines including PC3 and other 
prostate cancer. There are sparse reports for ERK activation in CaSR mediated signaling in 
osteoclast cells and other cancer cells (139, 140).  However, the CaSR mediated signaling 
pathway in cancer cells have not been systematic reported. In this Chapter, we aim to investigate 
calcium/CaSR mediated signaling pathway in prostate cancer cells using endogenous expressed 
CASR and compared it with transient expressed CASR with GFP tag in HEK293. In addition, 
HEK cell 5001 with CaSR stable expression will also be compared. Intracellular calcium 
oscillation induced by extracellular calcium, and the effect agonist and antagonist on the calcium 
oscillation will be examined. In addition, ERK activation and IP production will be studied.  
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5.3 Results 
5.3.1 Extracellular calcium induced calcium oscillation in HEK293 cell transfected with 
CaSR  
Fura-2 was used to measure intracellular calcium concentration. Kd for fura-2 is about 
225 nM measured in buffer. In our study, we first measure Kd of fura-2 in real time cytosolic 
environment of HEK293 cell. HEK293 cell were incubated with fura-2 and ionomycin was 
added to make cell membrane transportable for calcium ion. Therefore, intracellular calcium 
concentration changed with the change of extracellular buffer. Kd of fura-2 is about 579 nM after 
curve fit and data analysis using equation of m3*(m0^m1/(m2^m1+m0^m1))+m4; m1=2.6; 
m2=0.6; m3=0.4; m4=0.9. (Fig 5.1) The determined Kd is very close to the reported 640 nM 
(141). 
             As shown in Fig 5.2, the increase of extracellular calcium concentration in HEK293 cell 
did not result in intracellular calcium oscillation, but caused oscillation in HEK293 transfected 
with CaSR cells.  The extracellular calcium concentration required to trigger calcium oscillation 
is 3 mM, the frequency is 0.025. Such oscillation behavior is consistent with the previous 
observation by Chen Zhang (30).    
             To ensure the expression of CaSR in HEK cells and monitor its cellular location of 
expressed CaSR, next we examine the intracellular calcium oscillation using CaSR tagged with 
GFP at the C-terminal. Since the green fluorescence of GFP can help to differentiate the 
transfected cells and the untransfected cells, the transfection rate can be calculated. The green 
fluorescence of GFP does not affect the 340/380 intensity ratio at 510 nm to stand for the 
intracellular calcium concentration. Fig 5.5 shows that transfection with CaSR with GFP tag also 
induces calcium oscillation. The oscillation frequency is 0.024 and extracellular calcium required 
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to trigger calcium oscillation is 3 mM, which are all similar to HEK293 cell transfected with 
CaSR. These results suggest that the GFP tag does not affect the intracellular function of CaSR. 
The oscillation rate also can be calculated by counting the cell number. In the high cell density, 
the transfection rate is around 38% and the oscillation rate is around 38% too. In the low cell 
density, the transfection rate is around 8% and the oscillation rate is around 70% (Fig 5.6). The 
transfection rate and the oscillation rate in low cell density are higher than that of the high cell 
density. This is because the transfected CaSRGFP volume are all 1 μg. This volume is large 
enough to transfect most of the cells when the cell density is low. However, when the cell 
density is high, this volume is too little.  
These results showed that the oscillation cell number, the oscillation amplitude and the 
oscillation frequency of cells under 3 mM, 4 mM, 5 mM, 7.5 mM calcium concentration are 
higher than that of cells under 2 mM and 10 mM calcium concentration (Table 5.1). It seems that 
3 mM-7.5 mM calcium concentrations are the oscillation sensitive calcium concentration for the 
HEK293 cells transfected with CaSR. 
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Figure 5.1 Fura-2 calibration in HEK293 cell. A: HEK293 cells were incubated with fura-2 for 
20 minutes. Ionomycin was added to make calcium ion transportable across the biological 
membrane. 340/380 ratio was recorded when calcium buffer of different concentrations were 
added. B: Curve fit for fura-2 calibration with Kd of 579 nM. 
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Figure 5.2 HEK293 cell transfected with CaSR showed calcium oscillation. HEK293 and 
HEK293 cell transfected with CaSR were incubated with fura-2. The cells then were added with 
different concentration of calcium from 2mM to 5mM to see the intracellular calcium 
concentration change. The ratio of emission fluorescence under 340 over the emission 
fluorescence under 380nm excitation is regarded as intracellular calcium concentration. 
 
 
  Table 5.1 Analysis of oscillation of HEK293 transfected with CaSR 
 HEK293 transfected with CaSR 
added with 3-5mM calcium 
Oscillation starting point 3mM calcium 
Oscillation cell percentage 25% 
Oscillation amplitude 0.35±0.04 
Oscillation frequency 0.025±0.003 
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Figure 5.3 The oscillation of HEK293 cell transfected with CaSR changes with the change of the 
extracellular calcium concentration. HEK293 cell transfected with CaSR were incubated with 
fura-2. The cells then were added with different concentration of calcium from 1mM to 10 mM 
to see the intracellular calcium concentration change. The ratio of emission fluorescence under 
340 over the emission fluorescence under 380nm excitation is regarded as intracellular calcium 
concentration. 
 
  Table 5.2 Analysis of oscillation of HEK293 transfected with CaSR 
 HEK293 transfected with CaSR added with 3-
5mM calcium 
HEK293 transfected with CaSR added 
with 5-3mM calcium 
Oscillation starting point 3mM calcium 5mM calcium 
Oscillation cell number 20% 15% 
Oscillation amplitude 0.32±0.02 0.15±0.02 
Oscillation frequency 0.024±0.007 0.020±0.005 
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Figure 5.4 The oscillation cell number, the amplitude and the frequency of HEK293 cell 
transfected with CaSR.  HEK293 cell transfected with CaSR were incubated with fura-2. The 
cells then were added with different concentration of calcium from 2 mM to 10 mM to see the 
oscillation change. The oscillation cell number, the amplitude and the frequency were recorded 
to do the statistical analysis. 
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Figure 5.5 HEK293 cell transfected with CaSRGFP showed calcium oscillation. HEK293 cell 
transfected with CaSRGFP were incubated with fura-2. The cells then were added with different 
concentration of calcium from 2 mM to 5 mM to see the intracellular calcium concentration 
change. The ratio of emission fluorescence under 340 over the emission fluorescence under 380 
nm excitation is regarded as intracellular calcium concentration. The cells also were observed 
under 488 nm excitation to see the expression of CaSRGFP. 
 
 
 Table 5.3 Analysis of oscillation of HEK293 transfected with CaSRGFP 
 HEK293 transfected with 
CaSRGFP added with 3-5 mM 
calcium 
Oscillation starting point 3mM calcium 
Oscillation cell number 5±1 
Oscillation amplitude 0.32±0.02 
Oscillation frequency 0.024±0.006 
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Figure 5.6 The oscillation rate is corresponding to the transfection rate. The transfection rate of 
HEK293 cell transfected with CaSRGFP was calculated according to the presence of the GFP 
fluorescence. The oscillation rate was calculated according to the presence of the oscillation. 
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Figure 5.7 Non-transfected HEK293 cells showed calcium oscillation after neighbor CaSRGFP 
transfected cell showed oscillation. HEK293 cell transfected with CaSRGFP were incubated with 
fura-2. The cells then were added with 5 mM calcium to see the intracellular calcium 
concentration change. The ratio of emission fluorescence under 340 over the emission 
fluorescence under 380 nm excitation is regarded as intracellular calcium concentration. The 
cells also were observed under 488 nm excitation to see the expression of CaSRGFP. 
 
A                                                        B 
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Figure 5.8 Non-transfected HEK293 cells showed calcium oscillation after neighbor CaSRGFP 
transfected cell showed oscillation. HEK293 cell transfected with CaSRGFP were incubated with 
fura-2. The cells then were added with 5mM calcium to see the intracellular calcium 
concentration change. The ratio of emission fluorescence under 340 over the emission 
fluorescence under 380 nm excitation is regarded as intracellular calcium concentration. The 
cells also were observed under 488nm excitation to see the expression of CaSRGFP. 
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When we use CaSRGFP to transfect HEK293 cells, it is easy to differentiate transfected 
cells by observing the green fluorescence of cells. Sometimes, when we found oscillating cells 
with green fluorescence, we found the nearby cells which don’t show green fluorescence could 
also oscillate. In Fig 5.7 and 5.8, it is observed that when two HEK293 cells contact each other, 
one is transfected with CaSRGFP, the other one is not, the oscillation of transfected one will 
induce oscillation of untransfected one. The mechanism may involve calcium conduction 
through gap junction between two cells and ATP release from oscillating cells affecting 
surrounding cells. This possibility will be examined in future studies. 
 
5.3.2 Monitoring intracellular calcium oscillation in PC-3  
Fig 5.9 shows that in PC-3 cell, the oscillation effect was not seen when calcium was 
added gradually. However, the oscillation was observed when added with 20 mM or 30 mM 
calcium directly. HEK293 showed no oscillation when added with calcium from low 
concentration to high concentration gradually. HEK293 showed no oscillation either, when 
added with high concentration of calcium directly. 
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Figure 5.9 PC-3 cells don’t show calcium oscillation when calcium was added gradually but 
showed oscillation when 20-30 mM calcium was added directly. HEK293 and HEK293 
transfected with CaSRGFP cells don’t show oscillation when high concentration of calcium was 
added directly. Cells were incubated with fura-2. The cells then were added with different 
concentration of calcium from 3mM to 30mM gradually to see the intracellular calcium 
concentration change. The ratio of emission fluorescence under 340 over the emission 
fluorescence under 380nm excitation is regarded as intracellular calcium concentration.  
 
 
5.3.3 MDA-MB-231 breast cancer cell’s response to calcium 
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Same as PC-3 cells, MDA-MB-231 cells don’t show calcium oscillation when calcium 
was added gradually but showed little oscillation when high concentration of calcium was added 
directly. 
 
Figure 5.10 MDA-MB-231 cells don’t show calcium oscillation when calcium was added 
gradually but showed little oscillation when high concentration of calcium was added directly. 
MDA-MB-231 cells were incubated with fura-2. The cells then were added with different 
concentration of calcium from 3 mM to 30 mM to see the intracellular calcium concentration 
change. The ratio of emission fluorescence under 340 over the emission fluorescence under 
380nm excitation is regarded as intracellular calcium concentration.  
 
5.3.4 Comparison of oscillation in PC-3 with oscillation in HEK293 transfected with CaSR 
As shown in table 5.4, PC-3 and HEK293 transfected with CaSR showed different 
oscillation patterns when added with calcium. PC-3 showed calcium oscillation under the 
condition of being added with high calcium immediately. Compared to HEK293 transfected with 
CaSR, PC-3 has less oscillation cell number, lower amplitude and frequency of oscillation. EC50 
of HEK293 cell transfected with CaSR is 5 mM while PC-3 is 15 mM. 
Table 5.4 Comparison of oscillation pattern in PC-3 and in HEK293 transfected with CaSR 
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 HEK293 transfected with CaSR 
added with 3-5mM calcium 
PC-3 added with 20-
30 calcium directly 
Oscillation starting point 3mM calcium 20mM calcium 
Oscillation cell number 20% 3% 
Oscillation amplitude 0.35±0.04 0.32±0.02 
Oscillation 
frequency(Hz) 
1.5 1.1 
KD 5mM 19mM 
 
 
Figure 5.11 Comparison of oscillation pattern in PC-3 and in HEK293 transfected with CaSR. 
HEK293 cells transfected with CaSR and PC-3 cells were incubated with fura-2. The cells then 
were added with calcium to see the intracellular calcium concentration change. The ratio of 
emission fluorescence under 340 over the emission fluorescence under 380nm excitation is 
regarded as intracellular calcium concentration.  
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5.3.5 HEK293 transfected with CaSRGFP has responses to CaSR agonist and antagonist, 
but PC-3 doesn’t 
   R-568 is a CaSR agonist, which can promote the activation of CaSR. NPS-2143 is a 
CaSR antagonist, which can inhibit the activation of CaSR. From Figure 5.12, we can see R-568 
induced calcium oscillation at low calcium concentration of 2 mM, which generally does not 
induce the calcium oscillation. NPS-2143 inhibited calcium oscillation at 3 mM, 4 mM, and 5 
mM calcium, which are the oscillation sensitive calcium concentration range. However, the PC-3 
cells do not have any response to the CaSR agonist and antagonist. Even when PC-3 cells were 
transfected with CaSR, they still did not respond to any extracellular calcium change. 
 
Figure 5.12 Effect of agonist and antagonist on calcium response in HEK293 transfected with 
CaSRGFP and PC-3 cells. Effect of transfection of CaSR on calcium response in PC-3. The cells 
were added CaSR agonist (R-568) and antagonist (NPS-2143) and calcium to see the emission 
fluorescence change at excitation of 340 nm and 380 nm under fluorescence microscope. 
5.3.6 IP1 production in HEK293 and PC-3 
120 
 
  IP1 is transformed from IP3. Its production can represent the production of IP3, which is 
the main signal in calcium induced Gαq pathway. The standard curve was made using known 
concentration of IP1 to demonstrate the availability of the kit. 5001 is the HEK293 cell stably 
transfected with CaSR 5001 cell and HEK293 transfected with CaSR showed IP1 production fit 
curve with the increase of calcium concentration. From the curve, Kd of calcium binding to 
CaSR can be calculated, which are 2.3 mM calcium and 2.9 mM calcium for 5001 and HEK293 
transfected with CaSR, respectively. However, PC-3 cannot get the fit curve for the IP, 
production is very low and the corresponding calcium imaging showed no oscillation 
consistently. 
 
Figure 5.13 Standard curve of IP1 test. Standard IP1 solution with known concentration was 
incubated with IP1-HRP conjugate and anti-IP1 antibody for 3 hours. Then substrate and stop 
solution were added to read absorbance at 450 nm. %B/BO=divide the net OD value of each 
standard IP1 by OD of zero IP1 and multiply by 100. 
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Figure 5.14 IP1 measurements of 5001 stable cell line and corresponding oscillation pattern. A. 
IP1 production of 5001 after treatment of calcium of different concentration. 5001 cells were 
incubated with different concentration of calcium for 1 hour. Then the cells were lysed and the 
supernatant were incubated with IP1-HRP conjugate and anti-IP1 antibody for 3 hours. Substrate 
and stop solution were added to read absorbance at 450 nm. B. Calcium oscillation of 5001 
induced by different concentration of calcium which corresponds to that of IP1 test. 5001 cells 
were incubated with fura-2. The cells then were added with different concentration of calcium 
from 1 mM to 30 mM to see the intracellular calcium concentration change. The ratio of 
emission fluorescence under 340 over the emission fluorescence under 380 nm excitation is 
regarded as intracellular calcium concentration. 
   A 
A
  
B 
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Figure 5.15 IP1 measurements of HEK293 transfected with CaSR and corresponding oscillation 
pattern. A. IP1 production of HEK293 transfected with CaSR after treatment of calcium of 
different concentration. HEK293 transfected with CaSR cells were incubated with different 
concentration of calcium for 1 hour. Then the cells were lysed and the supernatant were 
incubated with IP1-HRP conjugate and anti-IP1 antibody for 3 hours. Substrate and stop solution 
were added to read absorbance at 450 nm. B. Calcium oscillation of HEK293 transfected with 
CaSR induced by different concentration of calcium which corresponds to that of IP1 test. 
HEK293 transfected with CaSR cells were incubated with fura-2. The cells then were added with 
different concentration of calcium from 1 mM to 30 mM to see the intracellular calcium 
concentration change. The ratio of emission fluorescence under 340 over the emission 
fluorescence under 380 nm excitation is regarded as intracellular calcium concentration. 
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Figure 5.16 IP1 measurements of PC-3 and corresponding oscillation pattern. A. IP1 production 
of PC-3 after treatment of calcium of different concentration. PC-3 cells were incubated with 
different concentration of calcium for 1 hour. Then the cells were lysed and the supernatant were 
incubated with IP1-HRP conjugate and anti-IP1 antibody for 3 hours. Then substrate and stop 
solution were added to read absorbance at 450nm. B. Calcium oscillation of PC-3 induced by 
different concentration of calcium which corresponds to that of IP1 test. PC-3 cells were 
incubated with fura-2. The cells then were added with different concentration of calcium from 1 
mM to 30 mM to see the intracellular calcium concentration change. The ratio of emission 
fluorescence under 340 over the emission fluorescence under 380nm excitation is regarded as 
intracellular calcium concentration. 
A 
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Figure 5.17 Comparison of IP1 measurements of PC-3 and HEK293 transfected with CaSR. IP1 
production of HEK293 transfected with CaSR and PC-3 cell after treatment of calcium of 
different concentration. Cells were incubated with different concentration of calcium for 1 hour. 
Then the cells were lysed and the supernatant were incubated with IP1-HRP conjugate and anti-
IP1 antibody for 3 hours. Then substrate and stop solution were added to read absorbance at 450 
nm. 
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5.3.7 ERK phosphorylation in HEK293 and PC-3 
              ERK can be activated by extracellular calcium. As shown in Fig 5.18, ERK can be 
activated to obtain phosphorylation by the increase of extracellular calcium concentration. In PC-
3 cell, ERK also can be activated by calcium. However, when the calcium concentration 
increased, the phosphorylated ERK did not increase beyond 2 mM. 
 
                         HEK293 + CaSR                                        PC-3 
                                                                                                      
 
 HEK293 + CaSR                              PC-3                              
                                                   
Figure 5.18 ERK phosphorylation in HEK293 transfected with CaSR and PC-3 cells. HEK293 
cells transfected with CaSR and PC-3 cells were treated with different concentrations of calcium 
buffer at 37 degree for 10 minutes. The cells were collected and lysed in RIPA buffer, loaded on 
12% SDA-PAGE gel. Polyclonal ERK antibody and polyclonal phosphor-ERK antibody were 
used to detect the proteins. 
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5.3.8 Gα expression in 5001 and PC-3 
              The difference between HEK293 and PC-3 cell in terms of oscillation patter and 
signaling pathway makes us suspect the difference of Gα protein expression in them. The 
activation of most of class C GPCR proteins will trigger Gα protein to transduct signals. Using 
antibody of Gα protein (ab58916 from Abcam) to detect Gα protein by western blot, we found 
both cell lines express Gα protein. Since Gq and G11 contributed to the calcium signaling, we 
need further examine such possibility by using antibody against Gq and G11 as well as 
overexpression of these G proteins. 
 
5.19 Expression of Gα protein in PC3 and 5001 cell. The cells were collected and lysed in RIPA 
buffer, loaded on 12% SDA-PAGE gel. Gα protein antibody was used to detect the proteins. 
 
 
5.3.9 Summary of difference between HEK293 and PC-3 
                 As shown in Table 5.5, there are many differences among HEK293, HEK293 
transfected with CaSR, PC-3, and PC-3 transfected with CaSR cells in terms of CaSR’s 
molecular weight, oscillation pattern, IP1 production, and ERK phosphorylation. HEK293 has no 
CaSR expression. Therefore it has no oscillation, no IP1 production and ERK phosphorylation. 
HEK293 transfected with CaSR has dimer CaSR. It starts to oscillate from 3mM Calcium, 
having IP1 production and ERK phosphorylation in calcium concentration dependent way. PC-3 
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has monomer CaSR, starting to oscillate from 20mM calcium. It has IP1 production and ERK 
phosphorylation when stimulated by calcium, but not in a calcium concentration dependent way. 
PC-3 transfected with CaSR shows monomer and dimer CaSR. However, it has no oscillation. 
 
Table 5.5 Summary of the difference between HEK293, HEK293+CaSR, PC-3, and PC-3 
+CaSR 
 HEK293 HEK293 + CaSR PC-3 PC-3+CaSR 
Molecular weight None Dimer 250 kD Monomer 110-120 kD Monomer110-120 kD 
Dimer 250 kD 
Oscillation None Starts from 3mM Starts from 20mM None 
IP1 None Increase with the increase of 
extracellular calcium 
No production N/A 
ERK None Increase with the increase of 
extracellular calcium 
Maximal at 2 mM N/A 
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5.4 Discussion 
   CaSR is involved in the receptor mediated extracellular calcium signaling to produce 
IP3. Then the IP3 will bind to the IP3 receptor on the ER membrane and stimulate the release of 
calcium from the ER. The calcium will go back to the ER again. The exit and the reentering of 
calcium to the ER cause the cytosolic calcium concentration change called calcium oscillation. 
   In this study, CaSR or CaSRGFP plasmid was used to transfect HEK293 cells. Both of 
the plasmids induce the cells to have calcium oscillation. HEK293 cells transfected by CaSR 
showed calcium oscillation mostly under the extracellular calcium concentration of 3mM -7.5 
mM. 2 mM and 10 mM calcium seldom will initiate the oscillation. HEK293 cells transfected by 
CaSRGFP showed calcium oscillation. The transfection rate is corresponding to the oscillation 
rate. In most cases, the cell will show oscillation if it is transfected with CaSRGFP. HEK293 
cells transfected with CaSRGFP showed calcium oscillation at low calcium concentration when 
added with R-568 and showed no calcium oscillation at high calcium when added with NPS-
2143. It suggests the transfected CaSRGFP in HEK293 cells have CaSR’s normal function.  
    HEK293 cells were transfected with CaSRGFP, which enables the observation of 
CaSR distribution. It seems CaSR is not only expressed on the cell membrane but also in the 
cytoplasm. It is consistent with the results of expression of CaSR in oocytes (142). The CaSR in 
cytoplasm may be in the process of synthesis or has other functions besides sensing calcium on 
cell membrane. The GFP was fused into the C-terminal of the CaSR sequence, which means that 
the green fluorescence stands for the mature CaSR, not the nascent CaSR. Therefore, CaSR 
should have some function in the cytosol. Some aggregations and vesicles were seen in the cells 
transfected with CaSRGFP, which suggests the possibility of CaSR participating in the vesicle 
fusion and formation. Jung et al. demonstrated that CaSR may form a complex with caveolin-
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1(143). Sun et al. confirmed that CaSR is predominantly localized in caveolae of mouse 
cardiomyocytes (144). From our confocal image, we did see some green vesicles in the 
cytoplasm of HEK293 transfected with CaSRGFP. It is possible that CaSR is localized in 
caveolae in the HEK293 cell transfected with CaSR. 
    PC-3 cells have no calcium responses when calcium was added from low concentration 
to high concentration gradually. They have little calcium oscillation when high concentration of 
calcium (20-30mM) was added directly. This might be because the PC-3 cells were obtained 
from the bone metastatic site of prostate cancer. They are used to having high extracellular 
concentrations of calcium. However, their oscillation cell number, oscillation amplitude and 
frequency are very low compared to HEK293 cells transfected with CaSR. The low expression 
level and unglycosylated or partially glycosylated pattern of CaSR expression in PC-3 could 
cause this. It is reported by Rey et al, that colon cancer cell transfected by CaSR have calcium 
oscillation when extracellular calcium concentration is 3mM (145). However, in PC-3 cell, even 
if it is transfected with CaSR, it still not show oscillation when extracellular calcium 
concentration increased. This might be the difference between prostate cancer cell and colon 
cancer cell. Colon cancer seldom metastasizes to bone. They are more sensitive to calcium 
concentration change. 
    From IP1 tests results, it is believed that IP3 pathway is the main pathway in the 
calcium induced oscillation effect of HEK293 transfected with CaSR. The IP1 production curve 
can be fit and the Kd for 5001 cell (stably CaSR transfected HEK293 cell) and HEK293 CaSR 
transiently transfected cell are 2.3 mM and 2.9 mM respectively. However, for PC-3, the IP1 
production curve cannot be fit and the Kd cannot be calculated. IP3 pathway might not be the 
main pathway. That’s why its oscillation pattern is very weak. The lack of IP1 production and 
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calcium oscillation delay under physiological condition suggests that Gαq pathway is obstructed 
in PC-3 cells. 
   ERK phosphorylation is one part of MAPK pathway. It can be activated by calcium 
stimulation. This process must go through calcium-sensing receptor on cell membrane. ERK 
phosphorylation in HEK293 cells transfected with CaSR is extracellular calcium concentration 
dependent. However, in PC-3, the pattern is different, not concentration dependent. Some papers 
reported that ERK pathway is the main signaling for PC-3 to secret parathyroid hormone related 
protein when CaSR is activated by extracellular calcium (146,147). Yano et al. demonstrates that 
extracellular Ca
2+
 stimulates PTHrP release during  6-h incubation (1.5- to 2.5- and 3- to 4-fold 
increases in 3.0 and 7.5 mM Ca
2+
, respectively) in PC-3 cells through ERK phosphorylation.  It 
means ERK phosphorylation in PC-3 is also calcium dependent. In our study, it showed the 
strongest activation happened when extracellular calcium concentration is around 3-4 mM. The 
difference is we used 10 minutes incubation time while they incubated for 6 hours. 
   It is understandable that PC-3 cells cannot respond to extracellular calcium change is 
due to its monomer CaSR has no function. However, when PC-3 is transfected with wildtype 
CaSR shown as dimer, it still cannot respond to calcium change. It is possible that the dimer 
CaSR expressed in PC-3 does not go to membrane or PC-3 has biased CaSR signaling pathway. 
There are several possibilities for the different signaling pathways. It is possible cancer cells do 
not have Gα/Gq11, or have low expression, or mutation of G alpha subunit (148).  Liu et al. have 
reported that when Gαq is overexpressed in PC-3 cells, β-catenin/T-cell factor signaling is 
induced. Otherwise, it cannot be induced. Nebsit et al has also recently reported that Gα11 was 
mutated in hypercalcemia and hypocalcemia patients (149). Mutations at other proteins involving 
in the signal pathways may also contribute to this process. Thakker’s group has reported that 
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missense mutations of AP2 σ subunit (AP2S1) affecting Arg15, which forms key contacts with 
dileucine-based motifs of CCV cargo proteins, result in familial hypocalciuric hypercalcemia 
type 3 (FHH3), an extracellular calcium homeostasis disorder affecting the parathyroids, kidneys 
and bone (150). They reported that AP2S1 mutations decreased the sensitivity of CaSR-
expressing cells to extracellular calcium and reduced CaSR endocytosis, probably through loss 
of interaction with a C-terminal CaSR dileucine-based motif, whose disruption also decreased 
intracellular signaling. We detected PC-3 cell and 5001 cell both express Gα proteins. However, 
we haven’t done the expression level of Gαq or Gα11. We can further investigate the subunits of 
Gα proteins and the sequence of them in the two cell lines. Sun Xian et al. found there is Gαq 
and Gα11 expression in PC-3 cells.  Gαq expression is comparably low. Overexpression of Gαq 
will promote cell growth of PC-3 (151). To investigate the expression, mutation, or deletion of 
Gαq, we can also pull down Gα by RT-PCR or immunoprecipitation to be sent to do sequencing 
or mass spectrometry. We also can knock Gαq or Gαq mutants in to observe the effects. 
              All these possibilities can be verified by introduction of proper subunits required for the 
signaling and perform detailed genomic sequence analysis of cancer cells and cosmic data bases. 
Other possibility such as expression level, location and modification for such differential in 
signaling will be explained in next chapter. 
 
5.5 Conclusion 
   In summary, HEK293 cells transfected with CaSR can sense extracellular calcium 
change, starting from 3 mM. PC-3 starts to have oscillation when added with 20-30 mM calcium. 
IP3 pathway is the pathway of HEK293 transfected with CaSR cell sensing extracellular calcium 
but not the pathway for PC-3.  
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6 DETAILED ANALYSIS OF CALCIUM-SENSING RECEPTOR IN PC-3 CELLS 
6.1 Abstract 
             Calcium-sensing receptor is expressed in HEK293 cells transfected with CaSR as dimer 
of over 250 kD and monomer of 150 kD. However, in PC-3 cell, CaSR is monomer with 
molecular weight of 120 kD. Moreover, the expression level is much less compared to HEK293 
cells transfected with CaSR. Glycosylation, Mass Spectrometry, RT-PCR, and sequencing were 
done to investigate the difference between them. It is found that the 120 kD band of CaSR in PC-
3 might be nonglycosylated form. Using CaSRGFP plasmid, it is found that CaSR in HEK293 
cell transfected with CaSR is localized not only on cell membrane but also in cytoplasm, might 
be in caveolae. The expression of CaSRGFP in PC-3 might be in endoplasmic reticulum. RT-
PCR results showed CaSR in PC-3 might have altered exon 6 and 7. Further sequence analysis 
by Otogenetics was not conclusive since the CaSR in the genome was not mapped. However, the 
sequencing data showed there is minimal volume of two variants of CaSR in PC-3 with 
differences in 10 amino acids insertion. Mass Spectrometry detected CaSR peptide in HEK293 
cells transfected with CaSR, but not in PC-3 cells possibly due to low expression. More Mass 
Spectrometry results are in process. Methods for protein analysis and identification of 
endogenous CaSR as a membrane protein here are also developed. 
 
6.2 Introduction 
            Calcium-sensing receptor (CaSR) was first cloned from bovine parathyroid by Dr. 
Edward Brown. Later it was found human also has this kind of receptor, which is expressed on 
the cell membrane of parathyroid epithelial cell. Its main function is to regulate calcium 
homeostasis in human. When the calcium concentration in serum is too low, CaSR senses it and 
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transduct this signal into intracellular pathway to stimulate parathyroid hormone to be secreted. 
The parathyroid hormone can increase calcium concentration of serum by improving calcium 
absorption in intestine, calcium reabsorption in kidney, and osteolysis in bone.  
In HEK293 overexpression system, CaSR is reported to form a dimer in the ER and 
further modified with glycosylation in the Golgi. The molecular weight of functional dimer 
expressed on the plasma membrane in mammalian cells exceeds 280 kD (152). As shown in Fig 
4.1, the functional dimer under non-reduced condition can be converted to different monomers 
under reducing condition in the presence of β-mercaptoethanol. It has non-glycosylated CaSR 
monomer of 110 kD (1080 aa), partially glycosylated CaSR of 140 kD, and fully glycosylated 
CaSR of 160 kD.   
              Some cancer cell lines are also found to have CaSR expression, including prostate 
cancer, breast cancer, leyding cancer, ovarian cancer, colon cancer, parathyroid cancer, etc. 
Especially, in Liao’s paper, they detected CaSR by western blot and RT-PCR in prostate cancer 
cells, including PC-3 cells. CaSR is also expressed as dimer in many tissues and tumors, such as 
parathyroid gland (153), colon myofibroblasts (154), gastrinomas (155), colon adenocarcinoma 
(156), etc. However, we found that HEK293 cells transfected by CaSR express 150 kD monomer 
CaSR and over 250 kD dimer CaSR (Fig4.1). Similarly, in breast and prostate (157) tissues or 
cells, it is expressed as monomer with molecular weight of 120-170  kD, which is consistent with 
our results. 
               However, in PC-3 cells and other prostate cancer cells, CaSR only show one monomer 
band of 120 kD. The big difference between them attracts our attention to investigate further. 
                Fig. 4.1 and 6.3 shows CaSR expression in several human endogenous cell or tissues 
based on literatures (158,159). In contrast to the reported dimer in overexpressed  HEK293 cell, 
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CaSR is not reported in human endogenous system without overexpression,. CaSR was reported 
to have the size of 120-140 kD in human parathyroid gland extracts depending on the 
glycosylation situation (160). Cetani et al. detected two major bands of 120-150 kD in normal 
parathyroid tissue but the intact glycosylated bands of 90-140 kD in parathyroid adenomas (161). 
They detected dimer over 200 kD and monomer of 120-150 KD of CaSR in parathyroid tissue of 
rat, but only monomer of 150 kD in kidney and liver of rat (162). Interestingly, CaSR in 5001 
cells, a stable cell line of CaSR expression derived from HEK cells is also a dimer under 
nonreducing conditions. The expression pattern of CaSR in prostate cancer cells is not clear. 
              In this study, we first examine the expression and distribution of CaSR in different 
prostate cancer cells in comparison with HEK overexpression system. 
 
6.3 Results 
6.3.1 Expression of CaSR in PC-3 cells and other prostate cancer cells 
              To find the cause of PC-3 cells not having calcium oscillation and not responding to 
CaSR agonist and antagonist, the CaSR expression pattern was detected in HEK293 transfected 
with CaSR and the prostate cancer cells. As shown in Fig 6.1, the positive control, CaSR 
transfected HEK293 cells, has three major bands: the band at ~250 kDa is the dimer form of the 
receptor; the 150 kDa is the monomer form. However, only one strong band at ~120 kDa has 
been detected along with a faint band at ~95 kDa. Interestingly, all the other prostate cell lines 
exhibited similar pattern as PC3 cells.  
 
  It showed that the stably CaSR transfected HEK293 cells showed a glycosylated band of 
150 kD and a dimer band which exceeds 250 kD. The prostate cancer cells have CaSR 
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expression band around 110 kD. Prostate cancer cells express monomer or heterodimer of CaSR, 
having no dimmer. Some prostate cancer cell lines, such as PC-3, even showed isoforms of 
CaSR, which is about 100 kD. (Fig 6.1 and 6.2)  
  PC-3 cells were transfected with CaSR. It was observed that many bands over 110 kD 
were formed. To detect whether the big band is the dimer or not, β-mercaptoethanol was added. 
β-mercaptoethanol could  cleave disulfide bands in the dimer form of CaSR. From the Fig 6.2, 
we could  see that the dimer of transfected CaSR didn’t get disrupted when β-mercaptoethanol 
was added.  It suggested that the big band in PC-3 transfected with CaSR is not the dimer, but 
might be an aggregation.  
 
Figure 6.1 Expression of CaSR in HEK293 and prostate cancer cell lines. HEK293 is the 
negative control, which doesn’t express CaSR. HEK293 transfected with CaSR is the positive 
control. The other cells are all prostate cancer cells. The whole cell lysate was extracted and 
loaded on the gel. 
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Figure 6.2 Expression of CaSR in PC-3 cells with or without β-mercaptoethanol. PC-3 cells were 
transfected by wildtype CaSR using lipofectamine 2000. Cell lysate was extracted from PC-3 
cells and was loaded on gel with or without β-mercaptoethanol. 
 
 
Figure 6.3 Negative control of western blot without adding CaSR antibody. HEK293 cells, 
HEK293 cells transfected with CaSR and prostate cancer cells were loaded on gel and detected 
by western blot. In the process, the primary antibody of CaSR was not added to see the effects. 
 
6.3.2 Examination of CaSR’s distribution in HEK293 cells  
  It is not clear whether CaSR localizes only on cell membrane. The distribution of CaSR 
in HEK293 cell was investigated. HEK293 cells were transfected with CaSRGFP and then were 
incubated with CaSR antibody and Alexa555 conjugated secondary antibody sequentially. 
Therefore, green fluorescence stands for total CaSR; red fluorescence stands for CaSR on plasma 
membrane. It was measured by flow cytometry that the percentage of red fluorescence cell is 
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about the same as negative control HEK293. The percentage of green fluorescence cell is about 
10 folds higher than that of HEK293 cell. It suggests that HEK293 cells did express CaSRGFP. 
Most of the CaSRGFP is in the cytoplasm, not on cell membrane. 
  
Figure 6.4 Fluorescence percentage of HEK293 cell transfected with CaSRGFP measured by 
flow cytometry. HEK293 cells without CaSRGFP transfection were incubated with CaSR 
antibody and Alexa555 conjugated secondary antibody. HEK293 cells with CaSRGFP 
transfection were incubated with CaSR antibody and Alexa555 conjugated secondary antibody.  
 
6.3.3 CaSR is localized differently in HEK293 cells and PC-3 
    The green fluorescence of GFP allows us to probe the localization of CaSR. 2-4 µg 
CaSRGFP plasmid was transfected into HEK293 cell for 2 days. Cells were fixed, washed, 
added with DAPI mounting reagent, and then observed under confocal microscope. As shown in 
Fig 6.5, it seems that CaSR is not only localized on the membrane but also localizes around the 
nucleus. It is not in ER or mitochondria since there is no overlap when ER tracker or 
mitochondria tracked were added. In some cells, it localizes on some vesicles to form 
aggregation. Membrane fluorescence intensity does not increase with the increase of transfection 
volume. CaSR in HEK293 and in PC-3 cells have different localization. In HEK293, CaSR is 
probably localized in endocytosis related caveolae. Jung et al. reported that CaSR and caveolae-1 
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can form complex. They are colocalized at plasma membrane (163). In PC-3, most of CaSR is 
probably localized in ER while some of them on the membrane.  
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Figure 6.5 Localization of CaSRGFP in HEK293 cells. A. CaSRGFP expression in HEK293 cell 
for 2 days observed under confocal microscope using Z-stack technique. The green fluorescence 
stands for the protein.  B. Localization of CaSRGFP in HEK293 cell compared with endoplasmic 
reticulum(ER) using ER Dsred transfection. Localization of CaSRGFP in HEK293 cell 
compared with mitochondria using mitochondria tracker. C Zoom in of the HEK293 cell 
transfected with CaSRGFP. (63×). 
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Figure 6.6 Observation of localization of CaSRGFP in HEK293 cells with the increase of 
transfection volume. HEK293 cells were transfected with different volume of CaSRGFP 
plasmids for 2 days. The cells were fixed by formaldehyde and observed under confocal 
microscope. 
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Figure 6.7 Observation of membrane CaSRGFP in HEK293 cells with the increase of 
transfection volume. HEK293 cells were transfected with different volume of CaSRGFP 
plasmids for 2 days. The cells were fixed, incubated with CaSR antibody, then secondary 
Alexa488 conjugated secondary antibody and observed under confocal microscope. 
 
                                 
HEK293 transfected with CaSRGFP          PC-3 transfected with CaSRGFP 
Figure 6.8 CaSRGFP expression in HEK293 cell and PC-3 cell observed under confocal 
microscope. HEK293 cells and PC-3 cells were transfected with CaSRGFP for 2 days separately. 
Cells were fixed on coverslips and stained with DAPI, then observed under confocal microscope.  
 A                                                                        B 
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Figure 6.9 Localization of CaSRGFP in PC-3 cells. A. CaSRGFP expression in PC-3 cell 
observed under confocal microscope using Z-stack technique. The green fluorescence stands for 
the protein.  B. Localization of CaSRGFP in PC-3 cell compared with non-transfected PC-3 
 
Figure 6.10 Localization of CaSR in PC-3 cells transfected with CaSRGFP. CaSRGFP 
expression in PC-3 cell was observed under confocal microscope using Z-stack technique. The 
green fluorescence stands for the protein.  Localization of ER and mitochondria were shown by 
ER tracker and mitochondria tracker separately. 
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Figure 6.11 Comparison of E-cadherin and CaSR on membrane and cytoplasm localization. PC-3 
control knock down cells and PC-3 CaSR knock down cells were fixed, incubated with E-
cadherin antibody or CaSR antibody, and both are stained with Alexa555 conjugated secondary 
antibody. 
 
  E-cadherin is a well known membrane expressed protein. By comparing the localization 
of CaSR and E-cadherin, it suggests CaSR is not only expressed on cell membrane of PC-3 cells 
but also in cytoplasm, especially around the nucleus (Fig 6.11). This is similar to the localization 
of CaSR in HEK293 cells transfected with CaSR or CaSRGFP. 
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Figure 6.12 Biotin assay of membrane CaSR expression in PC-3. HEK293 cells, 5001 cells, and 
PC-3 cells were incubated with biotin first. Cells were lysed in RIPA buffer. CaSR was 
immunoprecipitated with anti-CaSR antibody and protein A agarose. Samples were denatured in 
SDS sample buffer without beta-mercaptoethanol and electrophoresised by 8% SDS-PAGE. 
Biotinated-CaSR were visualized using VECTASTAIN ABC immunoperoxidase reagent. 
 
Biotin assay assists to detect cell membrane expression of protein. Biotin is pre-incubated 
with cell membrane before cell is lysed and pulled down by CaSR antibody. The pulled down 
protein which is visualized by biotin reagent is the membrane expression of CaSR. Fig 6.12 
shows PC-3 cells showed same bands in biotin assay as in western blot. It suggests that 
membrane CaSR in PC-3 cells is not dimer. It is also monomer as cytosolic CaSR. 5001 is stably 
CaSR transfected HEK293 cell. Biotin assay showed CaSR in 5001 is not on cell membrane, 
which is consistent with confocal observation that most CaSRGFP is in cytoplasm. 
 
 
 
6.3.4 Glycosylation of CaSR in PC-3 cells  
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             Protein extracted from the CaSR transfected HEK293 cells was subjected to two 
different glycosidase respectively: PNGase, which cleaves all the glycans from denatured 
protein; Endo F1, which only cleaves high-mannose type of glycans.  Both PNGase and Endo F1 
could reduce the size of the monomer receptor. However, the ADD stained immunoblot band 
couldn't be reduced to lower molecular weight by treatments with either of the enzymes in PC-3 
cells. (Figure 6.13). Thus, the results suggest that the glycosylation pattern of the CaSR in PC3 
cells is different from the CaSR transfected in HEK293 cells.   
                                   A                                                                        B 
 
                
Figure 6.13 The glycosylation pattern of CaSR in PC3 cells. Total proteins (20 μg) from CaSR 
transfected HEK293 cell lysates (A) and 100 μg of proteins from PC3 cell lysates (B) were 
applied to SDS-PAGE under reducing condition after treatment with PNGase or Endo F1. (C) 
Total proteins from 5001 and PC-3 cells were applied to SDS-PAGE after treatment with 
PNGase and Endo F1. 
6.3.5 SDS-PAGE Separation of CaSR in PC-3 for Mass spectrometry 
C 
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Since ADD peptide could not block the CaSR expression in PC-3 cells, it was necessary 
to identify the band around 120K detected by CaSR antibody in PC-3 cells. About 40 10-cm 
dishes of PC-3 and 10 10-cm dishes of 5001 and HEK293 transfected with CaSR cells were 
scratched down and lysed in RIPA buffer. After centrifugation, the supernatant was taken to be 
incubated with control agarose beads for 1 hour at 4 degree to remove unspecific binding 
proteins. After centrifugation, take the flow-through to be incubated with CaSR ADD antibody 
and protein A agarose beads overnight at 4 degree. The next day, the beads were washed three 
times and eluted by SDS-PAGE loading buffer. The eluted proteins were loaded onto SDS-
PAGE gel to run electrophoresis. The gel was stained in Coomasie blue. CaSR in PC-3 cells was 
separated from other proteins using SDS-PAGE gel after immunoprecipitated by CaSR antibody 
as seen in Fig 6. 14. CaSR expression in PC-3 cells was very little compared to that in 5001. The 
faint CaSR band in gel was sent to Dr. Ronghu Wu’s lab at Georgia Tech to do mass 
spectrometry. 
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Figure 6.14 SDS-PAGE separation of immunoprecipitated CaSR from PC-3 cells and 5001 cells. 
40 dishes of PC-3 cell and 10dishes of 5001 cells were lysed and incubated with calcium-sensing 
receptor antibody and the protein A agarose at 4 degree overnight with shaking. The next day the 
agarose bead was washed and added with loading buffer with beta-mecaptoethanol. The 
supernatant were loaded on the SDS-PAGE gel after centrifugation. The gel was stained with 
Coomassie blue after electrophoresis. 
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   Table 6.1 Mass results of band in 5001 cell  
6 9 sp|Q12789|TF3C1_HUMAN 
6 8 sp|P60709|ACTB_HUMAN 
6 6 sp|Q13459|MYO9B_HUMAN 
6 6 sp|P49327|FAS_HUMAN 
6 6 sp|P27708|PYR1_HUMAN 
6 6 sp|Q93008|USP9X_HUMAN 
4 7 sp|P10809|CH60_HUMAN 
4 4 sp|P41180|CASR_HUMAN 
 
 
      Table 6.2 Mass results of band in HEK293 transfected with CaSR cell  
27 27 sp|P78527|PRKDC_HUMAN 
25 25 sp|Q6P2Q9|PRP8_HUMAN 
16 16 sp|O75369|FLNB_HUMAN 
16 16 sp|Q92616|GCN1L_HUMAN 
12 14 sp|P41180|CASR_HUMAN 
 
 
   Table 6.3 Mass results of band in 5001 cell  
5 6 sp|Q9ULV0|MYO5B_HUMAN 
5 6 sp|Q92614|MY18A_HUMAN 
4 6 sp|P11277|SPTB1_HUMAN 
4 5 sp|P41180|CASR_HUMAN 
 
 
              As shown in Table 6.1, 6.2, 6.3, Dr. Ronghu Wu’s lab of Georgia Tech detected CaSR 
in 5001 cell and HEK293 transfected with CaSR. Firstly, they did in-gel digestion of the cut 
band and dried peptide samples. Then they dissolved peptides in a solution of 5% ACN and 4% 
formic acid. After being packed with C18 beads, peptides were separated by reversed-phase 
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chromatography and detected in a hybrid dual-cell quadrupole linear ion trap-Orbitrap mass 
spectrometer (LTQ Orbitrap Elite, ThermoFisher, with a software of Xcalibur 2.0.7 SP1). 
However, they cannot find CaSR in PC-3. 
 
 
Figure 6.15 Sample peaks separated by High Performance Liquid Chromatography (HPLC). 
Protein extraction samples were digested by trypsin and removed of amine-based buffers and 
thiol reagent. The samples were then loaded into Strong-cation Exchanger of HPLC to separate 
different fractions. Upper left: 5001 cytosolic proteins. Upper right: 5001 membrane proteins. 
Lower left: PC-3 cytosolic proteins. Lower right: PC-3 membrane proteins. 
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Table 6.4 Mass results of band in 5001 cell membrane 
  Score Proteins Unique 
peptides 
Amino Acids 
P40926 Malate dehydrogenase, mitochondrial OS=Homo sapiens GN=MDH2 
PE=1 SV=3 - [MDHM_HUMAN] 
1190.34 2 12 338 
P40939 Trifunctional enzyme subunit alpha, mitochondrial OS=Homo sapiens 
GN=HADHA PE=1 SV=2 - [ECHA_HUMAN] 
598.30 2 9 763 
P41180 Extracellular calcium-sensing receptor OS=Homo sapiens 
GN=CASR PE=1 SV=2 - [CASR_HUMAN] 
363.96 2 10 1078 
P42126 Enoyl-CoA delta isomerase 1, mitochondrial OS=Homo sapiens 
GN=ECI1 PE=1 SV=1 - [ECI1_HUMAN] 
302.37 3 4 302 
P42704 Leucine-rich PPR motif-containing protein, mitochondrial OS=Homo 
sapiens GN=LRPPRC PE=1 SV=3 - [LPPRC_HUMAN] 
1841.90 3 28 1394 
 
 
             Under Dr. Zou Jin’s guidance, we extracted membrane proteins and cytosolic proteins 
separately from PC-3 cell and 5001 cell using Membrane Protein Extraction kit (Thermo 
Scientific 89842). According to protocol of TMT Isobaric Mass Tagging Kit (Thermo Scientific 
90063), samples were reduced, alkylated and digested overnight after removing amine-based 
buffers and thiol reagent. Strong-cation exchange fractionation simplified complex samples into 
fractions. We sent fractions of each sample to Dr. Guangdi Wang of Department of Chemistry of 
Xavier University of Louisiana to do mass to see whether there is CaSR in PC-3. 
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Figure 6.16 Specificity of ADD antibody to CaSR expression in HEK293 and PC-3 cells. 
HEK293 cell and PC-3 cell were transfected with CaSR. Cell lysates were extracted and boiled 
at 42 °C, then loaded on the gel. A,B were added with β-mercaptoethanol. C, D were not added 
with β-mercaptoethanol. B, D were added with Add peptide to block ADD antibody. A, C were 
not added with ADD peptide. 1mg ADD peptide was dissolved in 1ml PBS. 2µl of it were added 
to 1ml of antibody solution (1:1000 dilution of 1mg/ml concentration) to incubate 30 minutes at 
room temperature. 
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Figure 6.17 Specificity of ADD antibody to CaSR expression in HEK293 and PC-3 cells. 
HEK293 cell and PC-3 cell were transfected with CaSR. Cell lysates were extracted and boiled 
at 60 °C, then loaded on the gel. M: β-mercaptoethanol. B was added with ADD peptide to block 
ADD antibody. A was not added with ADD peptide. 1mg ADD peptide was dissolved in 1ml 
PBS. 20µl of it were added to 1ml of antibody solution (1:1000 dilution of 1mg/ml 
concentration) to incubate 30 minutes at room temperature. 
 
Figure 6.18 Specificity of ADD antibody to CaSR expression in HEK293 and PC-3 cells. 
HEK293 cell and PC-3 cell were transfected with CaSR. Cell lysates were extracted and boiled 
at 60 °C, then loaded on the gel. M: β-mercaptoethanol. B was added with ADD peptide to block 
ADD antibody. A was not added with ADD peptide. 10mg ADD peptide was dissolved in 10ml 
Carbonate Buffer (pH9.6). 2µl of it were added to 1ml of antibody solution (1:1000 dilution of 
1mg/ml concentration) to incubate 60 minutes at 37°C. 
A                                                                                 B 
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Figure 6.19 Specificity of ADD antibody to CaSR expression in HEK293 and PC-3 cells. 
HEK293 cell and PC-3 cell were transfected with CaSR. Cell lysates were extracted and boiled 
at 60 °C, then loaded on the gel. M: β-mercaptoethanol. B was added with ADD peptide to block 
ADD antibody. A was not added with ADD peptide. 10mg ADD peptide was dissolved in 10ml 
Carbonate Buffer (pH9.6). 20µl of it were added to 1ml of antibody solution (1:1000 dilution of 
1mg/ml concentration) to incubate 60 minutes at 37°C. 
 
 
 
 
 
 
Figure 6.20 ADD peptide blocking experiment with various cell lines. (Left) Schematic 
representatipn of the ADD peptide blocking experiment. (Right) Total proteins (100 µg) from 
cell lysates of various prostate cancer cell lines were applied to SDS-PAGE and blotted with 
ADD, at 1:1000, with or without the presence of same concentration of the ADD peptide.  
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To test that the band of PC-3 is really CaSR or not, we used add peptide which is the 
immunogen of the CaSR antibody to block the CaSR antibody to see the effect on Western blot 
results. As shown in Fig 6.15, since we used 42°C of water to denature the proteins, there is no 
dimer band of CaSR. It might be because that 42°C is not high enough to denature the CaSR. As 
shown in Fig 6.16, HEK293 transfected with CaSR has band higher than 250K, which should be 
dimer of CaSR. After being added with ADD peptide, the dimer band disappeared. It suggested 
that the band is really the CaSR. Once the CaSR antibody binds to add peptide, the CaSR protein 
cannot be detected by the antibody. From Fig 6.17, we can see that binding of CaSR antibody to 
CaSR protein of HEK293 cell transfected with CaSR can be blocked by ADD peptide. However, 
the binding of CaSR antibody to CaSR protein in PC-3 cannot be blocked. After being added 
with add peptide, the CaSR band still can be seen. Fig 6.18 and 6.19 confirmed the results that 
CaSR band of PC-3 cell cannot be blocked by add peptide. It means that the band might not be 
CaSR or the CaSR in PC-3 has mutation which is different from add sequence.  
 
6.3.6 Sequencing of CaSR in PC-3 cells 
             There are 7 exons in CaSR. Alice in our lab found that PC-3’s exon 6 and exon 7 cannot 
be amplified by RT-PCR while 5001 can. As shown in Fig 6.20 and Fig 6.21, PC-3 only shows 
band of E5 with 5001 together. Then we extracted total RNA from PC-3 and sent it to 
Otogenetics to sequencing the cDNA of PC-3. 
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Figure 6.21 RT-PCR of the CaSR in PC3 and 5001 cells. A total of 2 μl of the cDNA CaSR from 
PC3 and 1 μl of the cDNA CaSR from 5001 were used as templates in the PCR procedure 
respectively. All PCR reactions were using forward primer 23 and the indicated reverse primers.  
The Tm value was set to be 60 °C with 3 min elongation time. 40 μl of the PCR product from 
PC3 reactions and 20 μl of the PCR product from 5001 reactions were loaded into the gel.  
 
Figure 6.22 RT-PCR of the CaSR in PC3 and 5001 cells confirmation. A total of 2 μl of the 
cDNA CaSR from PC3 and 1 μl of the cDNA CaSR from 5001 were used as templates in the 
PCR procedure respectively. All PCR reactions were using forward primer 23 and the indicated 
reverse primers.  The Tm value was set to be 62 °C with 3 min elongation time. 40 μl of the PCR 
product from PC3 reactions and 5 μl of the PCR product from 5001 reactions were loaded into 
the gel.  
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             The sequencing results show that there are two variants with a low coverage of CaSR 
was detected out of 40 million reads in PC-3 cells. Two isoforms of CaSR NM_000388 and 
CaSR NM_001178065 both present in PC-3 cells. The difference between the two isoforms is 
NM_001178065 has ten more amino acids at aa537 position than that of NM_000388 (Figure 
6.22). It is hard to get exact ratio of two variants or to tell mixed clone or else by sequencing. 
RT-PCR might help to quantify it. The issue of insufficient coverage might come from low 
expression of this specific CaSR gene in the total mRNA pool. The volume of expression is too 
low to get mapping results. Minimal coverage of CaSR causes no alternative splicing may be 
analyzed. As shown in Fig 6.23, there is no CaSR in the second bottom tab. It is found some 
potentially novel isoforms or fragments, unknown intergenic transcripts in PC-3. Nobody knows 
what they are. It is possible isoform of CaSR also exists there.  
 
Figure 6.23 Model structure of two CaSR variants by Ken Huang. CaSR NM_001178065 is 
named insertion as shown in purple and CaSR NM_000388 is named as wild type as shown in 
yellow. 
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Figure 6.24 Mapping results of CaSR sequencing in PC-3 cells. Total RNA of PC-3 were 
extracted and sent to Otogenetics to do sequencing. 
 
   
       Table 6.5 Sequencing results of cDNA in PC-3 cell 
Cufflinks 
transfrag id 
Cufflinks 
locus id 
Reference gene id  
TCONS_00049364 XLOC_030738 CASR|NM_000388 
TCONS_00049365 XLOC_030738 CASR|NM_001178065 
TCONS_00049366 XLOC_030739 CSTA|NM_005213 
 
         We still need to do RT-PCR to confirm the results, using different primers and trying 
different annealing time to make sure we got the exon 6 and exon 7 of CaSR in PC-3. As shown 
in Fig 6.23, the bands of 56Rev, E7-2 and E7 were amplified using 56 for as forward primer. It 
means that exon7 exists in PC-3. The experiments were repeated using E72 forward and 56 
reverse, E76 forward and E7 reverse, 56 forward and E7 reverse. 56 forward primer is 
GTATAGTGATGAGACAGATGCCAGTGCCTGTAACAAG. 56 reverse primer is 
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TGAATTCACTACGTTTTCTGTAACAGTGCTGCCTCCAC. E7-2 reverse primer is 
CTGCTTTTCTGGGCCTCCAGGGAGTTCTGGTG. E7 reverse primer is 
GGTGTTGCGGGATGGCTTGAAGAGAATGATGTAG. E72 forward primer is 
CTACGCACCAGAACTCCCTGGAGGCCCAGAAAAGCAG. E76 forward primer is 
CACACCCATTGTCAAGGCCACCAACCGAGAG.  
A                                                                           B 
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Figure 6.25 RT-PCR of the CaSR in PC3 cells. A total of 4 μl of the cDNA CaSR from PC3 
were used as templates in the PCR procedure. In figure A, all PCR reactions were using forward 
primer 56 for and the indicated reverse primers.  The Tm value was set to be 58 °C with 2 min 
elongation time.  
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6.4 Discussion 
To investigate the reason for different functions of CaSR in PC-3 and HEK293 
transfected with CaSR cells, CaSR’s expression pattern in them were detected by western blot. 
Our western blot results showed that HEK293 cells don’t have CaSR expression. HEK293 cells 
transfected with CaSR showed the dimer band over 250 kD and the 150 kD band as a 
glycosylated one. All of the prostate cancer cells express CaSR, but the bands are about 120 kD, 
which is lower than the glycosylated one in HEK cell. The lowest band is about 110 kD, which 
might be the unglycosylated isoform or partially glycosylated isoform. It is consistent with the 
oscillation results that PC-3 has weaker oscillation patterns than that of HEK293 cells transfected 
with CaSR. 
              The difference between molecular weight of CaSR in PC-3 cells and HEK293 cells 
transfected with CaSR might be due to glycosylation. PNGase and endoF1 work well in cleaving 
CaSR I HEK293 cells transfected CaSR. They cleaved 150 kD glycosylated CaSR into partially 
glycosylated 130 kD CaSR and unglycosylated 120 kD CaSR. However, PNGase and endoF1 
didn’t cleave any part in CaSR of PC-3 cells. It suggested that CaSR in PC-3 has no 
glycosylation. Another possibility that the glycosylation of CaSR in PC-3 is very little, like only 
1 to 2 sites glycosylated. Western blot cannot differentiate this small change in molecular weight.          
Glycosylation change can be due to different post-translational modification or upstream 
signaling change, like Gαq’s low expression or mutation. 
           Alice amplified exon 2, exon 3, exon 4, and exon 5 of CaSR by RT-PCR using mRNA of 
PC-3 cells. Exon 6 and exon 7 cannot be amplified. Total mRNA of PC-3 was sent to sequence. 
The results show that there is minimal volume of CaSR in PC-3 cells so that splicing form 
cannot be done. The report showed there are two variants of CaSR in PC-3 cells. One is CaSR 
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NM_000388. The other is CaSR NM_001178065. The difference between the two isoforms is 
NM_001178065 has ten more amino acids at aa537 position than that of NM_000388. However, 
the coverage is very low, about 0.02, compared to GAPDH of 998. That’s why CaSR is not 
shown in mapping figure for the volume is too low. 
           The inserted amino acid sequence is PLTFVLSVLQ. The corresponding DNA sequence 
is ccactcacctttgtgctgtctgtcctccag. The production of the isoform is due to alternative splicing. The 
wild type CaSR plasmid we use to transfect HEK293 is the sequence without insertion. We can 
add this insertion sequence to make new CaSR plasmid then transfect cell to see the effects. This 
will help us understand the biased signaling in PC-3 cell. We also can use the insertion peptide as 
antigen to produce antibody to screen CaSR isoform in cancer tissues. With the antibody to 
variant with insertion and the antibody to wildtype variant, we can calculate the expression ratio 
of the two variants by western. The insertion peptide of REPLTFVLSVLQVPF and the wildtype 
peptide of WSGFSREVPFSNCSR have been synthesized (10 mg for each by United Biosystems 
Inc.). 
           Since ADD peptide cannot block the binding of CaSR ADD antibody to the band, it is 
doubted that the band detected is CaSR or not. Mass spectrometry identified CaSR in HEK293 
cells transfected with CaSR. However, CaSR in PC-3 cells cannot be detected. We improved 
immunoprecipitation methods and sent more samples.  
             If CaSR in PC-3 really miss exon 6 and exon 7 which are responsible for transmembrane 
and intracellular domain coding, CaSR should not be expressed on cell membrane. One 
possibility is that CaSR could be secreted from PC-3 cell into media. Another possibility is CaSR 
forms heterodimer with other GPCRs to sense the calcium. CaSR is always thought to function 
as homodimers in tissues, such as parathyroid gland and kidney. CaSR also can heterodimerize 
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with other receptors, like mGluRs (164). Gama et al. showed that CaSR co-immunoprecipitated 
with the mGluR1 and R5 in HEK293 cells. Jong et al. reported that GABA-B-R1 (GABA B 
receptor 1) can heterodimerize with CaSR (165, 166). Heterodimerization among subtypes of 
GPCRs can lead to signal enhancement or differences in trafficking or desensitization pathways. 
 
6.5 Conclusion 
              CaSR in HEK293 is expressed as glycosylated dimer of 250 kD and possible as a 
monomer of 150 kD. CaSR in PC-3 is unglycosylated monomer about 120 kD. CaSR is not only 
expressed on cell membrane but also in cytoplasm. CaSR in PC-3 may have altered DNA and 
amino acid sequence. Methods for analysis of endogenous CaSR and its interacted proteins have 
been developed. 
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7 SIGNIFICANCE AND MAJOR CONCLUSIONS 
Human prostate tissue microarrays are used to measure CaSR expression in normal 
human prostate tissue and prostate cancer tissue. It is found that there is no difference in terms of 
CaSR expression between normal human prostate tissues and prostate cancer tissues. There is 
also no difference in the CaSR expression between primary prostate cancer tissues found in 
prostate of patients with bone metastases and that of prostate cancer patients without bone 
metastases. However, there is a difference between the primary prostate cancer tissues found in 
prostate cancer tissue localized to the prostate, and metastatic prostate cancer tissues found in the 
bone. Our tissue microarray studies suggest that CaSR expression may increase after prostate 
cancer cells spread to the bone. This increase likely results from the prostate cancer cells 
adapting to the new, calcium rich environment and, thereby enhances their capacity to colonize 
in bone. 
To explore the governing mechanism of this phenomenon, Western blot, flow cytometry, 
viral infection knock down, and invasion assay was used to find the exact role that CaSR plays in 
the colonization process. It is found that upon the knockdown of CaSR in PC-3 cells, there was 
an increase in cell apoptosis, cell invasion, and epithelial-mesenchymal transition (EMT). This 
suggests that CaSR may inhibit cell apoptosis and cell invasion, while promoting mesenchymal-
epithelial transition (MET) when cancer cells begin to colonize the bone. Bone environment with 
high calcium is likely to play an important role in MET of cancer metastasis due to protection of 
apoptosis through CaSR. Our findings for cancer bone metastasis are likely applicable for other 
chronic diseases, like FHH and ADH. New type of cancer therapy against bone metastasis can be 
further developed by reducing CaSR at bone environment as well as by modulating extracellular 
calcium signaling in bone environment. 
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 The unglycosylated monomer band (120 KD) of CaSR was found in prostate and breast 
cancer cells. Compared to the expressed bands in HEK293 cells transfected with CaSR, CaSR in 
PC-3 cells has no dimer bands (250KD), expressing only monomeric CaSR. Furthermore, this 
monomer is confirmed to be expressed on cell membranes by biotin assay. This is noticeably 
different from the commonly accepted idea that CaSR always is present on cell membrane as a 
dimer. The function of CaSR in PC-3 is also different from that in HEK293 cells. CaSR in PC-3 
cannot induce calcium oscillation when the extracellular calcium concentration changes from 3 
mM to 7.5 mM.  The signaling pathway in HEK293 cells transfected with CaSR is the classical 
pathway of calcium stimulation through G protein coupled receptors. Calcium activates 
phospholipase C-β (PLCβ) through Gαq/11. The PLCβ catalyzes the cleavage of the 
phosphatidylinositol 4, 5- biphosphate into the inositol trisphosphate (IP3) and DAG. IP3 can 
bind to IP3 receptor on ER membrane to release the calcium from the ER. Since IP1 is the 
paraproduct of IP3, the amount of IP1 can stand for the amount of IP3. In contrast to HEK293 
cells transfected with CaSR with large IP1 production, in PC-3 cells, the amount of IP1 is not 
significant when stimulated by calcium. We have found a new form of CaSR as a monomer on 
the cell membrane in prostate and breast cancer cells. It has a different molecular weight 
(120KD), glycosylation pattern, and signaling pathway compared to that in normal cells. 
  In summary, we have first observation of monomer CaSR isoform with altered signaling 
pathway is likely to be shared by other cancers, especially in bone metastasis. The function of 
this monomeric CaSR is to allow and aid cancer cells in colonizing bone. Bone environment with 
high calcium is likely to play an important role in MET of cancer metastasis due to protection of 
apoptosis through CaSR. Our findings for cancer bone metastasis are likely applicable for other 
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chronic diseases, like FHH and ADH. New type of cancer therapy against bone metastasis can be 
further developed by reducing CaSR at bone environment as well as by modulating extracellular 
calcium signaling in bone environment. 
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